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 Parkinson’s Disease
Parkinson’s disease (PD) is a common neurodegenerative disease, affecting 
approximately 1.8% of the population over the age of 65.1 The prevalence of PD increases 
with age; it rises to 2.6% of the population between 85-89 years of age. James Parkinson 
described the disease called “shaking palsy (paralysis agitans)” for the ﬁrst time in 1817.2 The 
main clinical features of PD are motor symptoms such as, bradykinesia, rigidity, resting tremor 
and postural instability, which are related to the degeneration of nigrostriatal dopaminergic 
neurons. The neuropathological hallmark of PD is the presence of lewy bodies: distinctive 
neuronal inclusions that are mainly composed of structurally altered neuroﬁlaments.3 The 
diagnoses of possible and probable PD are based on the presence of clinical motor features, 
however neuropathological conﬁrmation is required for the diagnosis of deﬁnite PD.4 The 
pathogenesis of PD is currently unknown, but both genetic susceptibility and environmental 
factors (e.g., smoking, pesticide exposure) appear to play a role in the disease process.5-8 For 
a long time the main clinical focus in PD has been on the motor features, however, there is 
increasing recognition that the clinical spectrum of PD is more extensive, also including non-
motor features such as cognitive dysfunction,9 depression,10 sleep disturbances,11 autonomic 
disturbances,12 pain,13 and motor14 and psychiatric complications of therapy.15 Furthermore, 
within the PD population, there is marked clinical heterogeneity,16 which may suggest that 
subgroups of PD exist that not only differ in the presence and severity of different impairments, 
but may also vary with respect to the rate of disease progression. Awareness of the whole 
spectrum of PD may improve if a conceptual model that describes the different levels of PD 
is used.
The Disablement process
The disablement process is a sociomedical model that describes the pathway from 
pathology to disability via impairments and functional limitations, and incorporates intra and 
extra-individual factors that speed up or slow down the rate of disablement.17 Impairments 
are deﬁned as dysfunctions and signiﬁcant structural abnormalities in speciﬁc body systems, 
functional limitations are restrictions in performing basic physical and mental actions, and 
disability is the experienced difﬁculty doing activities of daily life. This conceptual framework 
is based on: (1) the scheme on disability by Nagi18 and (2) the International Classiﬁcation of 
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Impairments, Disabilities and Handicap (ICIDH) by the World Health Organization.19 The 
disablement process focuses on the consequences of disease rather than on disease etiology 
and forms a framework for research design or patient management.  
The disablement process may be used to describe the various domains at the 
impairment and disability level, and global outcomes of health that may be affected by PD. 
Figure 1 describes the disablement process in PD. At the impairment level the model includes 
cognitive dysfunction, mood disturbances, motor dysfunction, autonomic dysfunction, pain, 
sleep disruption/excessive daytime sleepiness (EDS), and motor and psychiatric complications 
of therapy. At the level of disability, difﬁculties with ADL and psychosocial functioning are 
incorporated into the model. The global outcomes of health include global health, utility and 
costs. This model summarizes the complete spectrum of the disease at a glance and can improve 
our understanding of the disease and the inﬂuence of personal and environmental factors.
Figure 1: The disablement process in PD
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Assessments in PD
 The evaluation of the functioning of patients with PD on the different domains 
of the disablement process requires a broad range of assessment scales. Although several 
assessment scales have been developed speciﬁcally for PD, the main focus has always been 
on motor impairments and activities of daily living (ADL), leaving out aspects such as, 
cognition, depression, sleep, or autonomic dysfunction. Furthermore, the majority of available 
rating scales has clinimetric shortcomings, or has not been subjected to clinimetric testing.20 
A clinimetric sound assessment scale should fulﬁll the following criteria: a high standard 
of reliability (test-retest reliability inter-rater reliability and internal consistency), a high 
standard of validity (content validity, factorial validity, criterion validity, and discriminant 
validity) and responsiveness (sensitivity to change). 
Aims of this thesis  
In preparation for a longitudinal study on the disablement process in PD, the aim 
was to construct a disease-speciﬁc model of the disablement process, encompassing all 
relevant domains in PD on the levels of impairments, disabilities, global outcomes and intra 
and extra-individual factors that act on this pathway. This model was constructed on the basis 
of literature review and of consulting experts in the ﬁeld of PD. 
Speciﬁc attention has been given to comorbidity as an intra-individual factor. The 
prevalence of both PD and comorbidity increase with advancing age and therefore many 
patients with PD will also suffer from other diseases related to old age (e.g. diabetes, 
osteoporosis).21;22 The presence of comorbid diseases will have consequences for disability, 
substantially adding to the disease burden, and this information should therefore be included 
in the disablement process.22
Following the construction of the model, for each PD domain an assessment scale 
was selected or developed. This project was called the SCales for Outcomes in PArkinson’s 
disease (SCOPA). Prerequisites for the assessment scales were good reliability, validity, 
and (potential) responsiveness. Furthermore, the design of the longitudinal project was that 
PD patients would be evaluated for all these domains simultaneously. Therefore, additional 
requirements for the assessment scales were that they were: (1) short, (2) practical, not 
requiring sophisticated measurement instruments, and (3) either self-assessed or could be 
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used by research personnel without demanding extensive training. A standard procedure was 
followed for assigning the assessment scales. If a clinimetrically sound scale was available 
for a PD domain, this scale was incorporated into the model. If a scale was available but the 
clinimetric properties of the scale in a PD population were unknown, this scale was evaluated 
in PD. If no scale was available for a domain, then this scale was developed and evaluated. In 
this thesis, the clinimetric evaluation and development of PD speciﬁc assessment scales on 
the levels of impairments, disability and intra-individual factors is described.
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Abstract
Objective: To determine which test for postural instability in Parkinson’s disease (PD) is 
reliable, valid and easy to perform in a clinical setting.
Design: Cross-sectional reliability and validity study.
Setting: Academic center for movement disorders. 
Patrticipants: Forty-two PD patients and 15 controls. The patients were based on the results 
of a structured interview divided in PD-unstable (N=22) and PD-stable (N=20).
Main Outcome Measures: Several variants of the retropulsion test with differences in 
execution and scoring. Responses were scored on ﬁve different rating scales (according 
to Nutt, Bloem, Pastor, the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) and the 
Short Parkinson Evaluation Scale (SPES)). These tests were compared with steady stance 
positions. 
Results: The interrater reliability was high for most ratings, weighted kappa’s ranged from 
0.63 for the UPDRS rating to 0.98 for both the Pastor rating and steady stance positions. Most 
ratings distinguished between the groups. However, the Nutt rating had the highest overall 
predictive accuracy, with a sensitivity of 0.63 and a speciﬁcity of 0.88. 
Conclusions:  The most valid test for postural stability in PD was an unexpected shoulder 
pull, executed once, with taking more than two steps backwards considered abnormal. This 
retropulsion test is easy to use in a clinical setting.  
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One of the four cardinal features of Parkinson’s disease (PD) is postural instability, 
which mostly develops later in the course of the disease. Balance in standing is achieved by 
keeping the body’s center of mass over the base of support. When the ability to maintain 
balance deteriorates, patients with PD are predisposed to falls, which is a common and serious 
problem in PD1. However, the relation between postural instability and falling is complex. 
First, falls are not only caused by postural instability, but can also be caused by freezing 
or involuntary movements2. Second, patients may prevent their falls by adjusting their 
behaviour3. Patients with postural instability experience balance problems and are therefore 
“at risk” for falling, but whether they fall or not depends also on their environment or daily 
activities4. Patients with postural instability who restrict their activities as a result of a so-
called “post-fall syndrome”5, would still be “at risk”, but do not actually fall6. Prevention of 
falls can be achieved in several ways for example, by the use of walking aids, by the support 
of bystanders before an actual fall, by the use of attentional strategies, or by the avoidance 
of risky situations.
A test for postural stability must assess the ability to maintain balance. The validity 
of the test can then be established by comparing the results to an external criterion. Although 
a history of falls7;8 is frequently used as the criterion, this does not include all possible balance 
problems. We therefore used the criterion of being “at risk” for falling. This includes, in 
addition to a history of falls, situations in which postural instability was experienced and also 
adaptations that were made to prevent falls.
Not only is the predictive ability of postural stability tests in question, but there 
are also problems with the execution of balance tests. For patients with PD, the clinical 
assessment of postural stability is usually performed by giving a sudden shoulder pull to 
the patient. This ‘retropulsion test’ appears to be very simple, but it is unclear how this test 
should be executed or how the balance reaction should be scored. Different variants exist, 
but none has been properly validated. Subjects can be instructed that taking corrective steps 
backward are allowed or not, and in both variants the number of corrective steps are used as 
a criterion for abnormality. There is no consensus how an ‘abnormal’ reaction to a shoulder 
pull should be deﬁned. It also remains unclear whether the shoulder pull should be ‘expected’ 
(no warning) or unexpected or whether the test should be executed just once or several times 
(to examine habituation effects). 
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Our study is part of a more extensive project, in which SCales for Outcomes in 
PArkinson (SCOPA) are developed and evaluated. One of these scales will evaluate motor 
functions in PD and include items addressing tremor, bradykinesia, rigidity and axial 
functions. The axial section will consist of “gait”, “arising from a chair”, and “postural 
stability”. However, it is not clear which test to include for the item of postural stability. The 
aim of this study was to examine which test for postural instability in PD is reliable, valid and 
easy to perform in a clinical setting.
Methods
All consecutive patients who visited the outpatient neurology clinic of the Leiden 
University Medical Center in April and May 2001, and who fulﬁlled the United Kingdom 
Parkinson’s Disease Society Brain Bank criteria for idiopathic PD9, were selected. Patients 
were excluded if they were unable to stand independently. Partners and relatives of patients 
participated in the control group, provided that they did not experience balance problems in 
daily life. 
Demographic data of the patients was recorded. The sections Motor Evaluation and 
Activities of Daily Living (ADL) of the Short Parkinson Evaluation Scale (SPES)10 were 
completed by an investigator to evaluate disease severity of the patients with PD. The local 
medical ethics committee approved the study protocol, and all patients gave informed consent 
before the assessment.
The following criteria were used to select tests for postural stability: (1) an existing 
test that is relatively easy to perform in a clinical setting without additional tools or personnel, 
(2) the test can be rated as a single item, and (3) the test evaluates the ability to maintain a 
posture (reactive postural responses)11. The retropulsion test is the most widely used test for 
postural stability in PD and several variants, differing in both execution and rating, were 
included. The outcomes of the retropulsion tests were scored on ﬁve different rating scales. 
In contrast to the retropulsion tests, a battery of increasingly difﬁcult steady stance positions 
was also included. The force of the shoulder pull may be difﬁcult to standardise, and this 
could introduce variability, therefore we added a test where no external perturbation was 
required. 
CHAPTER 2
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In total six rating methods were selected (see Appendix 1):
1.  Rating according to Nutt et al,12 evaluating the reaction to an unexpected (no prior 
warning) shoulder pull, and scored on a 4-point scale.
2.  Rating according to Bloem et al,13 evaluating the reaction to an unexpected (no prior 
warning) shoulder pull, and scored on a 4-point scale, this rating also includes the 
speed of restoring balance.
3.  Rating according to the Uniﬁed Parkinson’s Disease Rating Scale14 (UPDRS), 
evaluating the reaction to an expected (after prior warning) shoulder pull, and scored 
on a 5-point scale.
4.  Rating according to the SPES,10 evaluating the reaction to an expected shoulder pull, 
and scored on a 4-point scale.
5.  Rating according to Pastor et al,15 evaluating the reaction to an expected shoulder pull, 
and scored on a 5-point scale; this rating contains the speciﬁc prior instruction that 
subjects should try to restore balance without taking corrective steps backwards.
6.  Rating of steady-stance positions, rating the most difﬁcult of 4 positions that could 
be maintained for at least 5 seconds, and scored on a 5-point scale. 
The ratings were based on four standardised conditions and these balance tests were 
             performed as follows:
1. Shoulder pull unexpected: the examiner stands behind the subject and without prior 
warning, gives a sudden, ﬁrm and quick backward pull to the shoulders. 
2. Shoulder pull expected: the examiner stands behind the subject, informs the patient 
by saying “I am going to pull you right now” and immediately gives a ﬁrm and 
quick backward pull to the shoulders.
3. Shoulder pull expected, without stepping backward: executed the same way as the 
aforementioned test, but the subject is instructed not to take any steps backwards.
4. Steady standing tests: the subjects performed four stance positions in the following 
order: (1) two leg stance with the feet against each other, (2) tandem stance, (3) 
single-leg stance, and (4) single leg stance with the arms raised above the head. 
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Each of these four positions had to be maintained for at least 5 seconds. If the 
patient was not able to maintain a position for 5 seconds, the subject was allowed an 
immediate second attempt. Tandem stance was tested with one foot directly in front 
of the other foot; the test was executed both with the left and the right foot in front. 
The single leg stance tests were also performed for both sides. In this sequence of 
steady standing positions, the supporting surface became smaller in every subsequent 
position, ensuring a hierarchy of difﬁculty. Therefore, if a patient could not maintain 
a given position during two attempts, the next position was assumed to be impossible 
as well and was not performed. The positions were thus not individually rated but 
adapted to an overall rating to fulﬁl the criterion of a single-item.
To minimize differences in the force of the shoulder pulls as much as possible, 
the shoulder pulls were practised on healthy volunteers before the research started. One 
examiner (HK) executed all the postural stability tests. All tests were executed twice to 
examine habituation effects and to determine which execution is the most informative. 
The four conditions were performed in two different orders. The steady-stance tests were 
always the second test condition, and the shoulder pull with the instruction not to step was 
always the fourth test condition. The expected and unexpected shoulder pulls were applied 
in an alternating sequence. Patients and controls were randomly assigned to one of the two 
sequences.
All balance tests were taped on video. The subjects were recorded from the left 
lateral side. The video recordings were used to evaluate the responses to the balance tests. 
Three examiners (MV, JM, JJvH), who were blinded with respect to group allocation, 
independently rated the postural responses. After the assessment of postural stability, patients 
and controls were interviewed with a standardized questionnaire, including questions on 
their mobility in daily life, perception of balance, use of walking aids, housing situation, 
medication and comorbidity. 
The history of being “at risk” for falling included the frequency and circumstances 
of falls and near falls and strategies used to prevent falls in the last six months. A fall was 
deﬁned as an event that resulted in a person coming to rest unintentionally on the ground or 
other level, not as the result of a major intrinsic event or overwhelming hazard.16 A near-fall 
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was deﬁned as an occasion on which an individual felt that he/she was going to fall but did 
not.17 Based on the results of the interview, patients with PD were divided in two groups: 
PD-stable and PD-unstable. Patients were classiﬁed as “unstable” when they had at least one 
of the following features: two or more falls or near falls in the previous 6 months, used some 
sort of walking aid, or initiated other measures to prevent falling. Stable patients fulﬁlled 
none of these criteria, and the control group included only stable participants. 
Statistical Analysis
Data were analysed with SPSS,version 10.0,a for Windows. Characteristics of the two 
patient groups and controls were compared by using analyses of variances (ANOVAs), t tests 
for independent samples, and non-parametric statistics (χ2). Means and standard deviations 
(SDs) of each rating for the three groups were calculated, and the interrater reliability of the 
six ratings was assessed by using the mean of the three weighted kappas for each pair of 
raters (squared weighting scheme). The scores of each rating were averaged over the three 
raters and means were calculated for each group, separately for each test and for each of the 
two executions. Differences were analysed by using ANOVAs and post hoc t tests. 
The predictive criterion validity was assessed in the PD group by calculating the 
sensitivity and speciﬁcity to classify patients into either the PD-stable or PD-unstable group. 
For these calculations, the rating 0 was considered a normal score, whereas deviant scorings 
were ratings of 1 or higher. The sensitivity was calculated by the fraction of unstable patients 
identiﬁed as positive by the test (score > 0), and the speciﬁcity by the fraction of stable patients 
correctly identiﬁed as negative by the test (score = 0). Additionally, the positive predictive 
value was calculated by the proportion of patients with a positive test result (score > 0) who 
were unstable, and the negative predictive value by the proportion of patients with a negative 
test result (score = 0) who were stable. The overall predictive accuracy was calculated as the 
proportion of all patients classiﬁed correctly by the test: PD-unstable patients with a positive 
test and PD-stable patients with a negative test result. These values were calculated for each 
rating and test execution and averaged over the three raters. 
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Results 
Characteristics of the participants
Forty-two patients with PD and 15 healthy volunteers participated. Based on the 
results of the questionnaire on being at risk for falling, 20 patients with PD were considered 
stable and 22 unstable. Both PD groups were similar for age, sex, disease duration, and use 
of medication (Table 1). The controls were comparable with both PD groups for age and sex. 
Compared with the PD-stable group, the PD-unstable group spent signiﬁcantly less time 
outdoors, indicated a signiﬁcantly shorter maximum walking time, and had higher scores 
on the SPES ADL and SPES motor evaluations. The PD-stable group did not differ from the 
controls with respect to the time spent outdoors or the maximum walking time. 
Table 1: Characteristics of subjects 
PD-unstable
(n=22)
PD-stable
(n=20)
Controls
(n=15) p
Male/female 9/13 13/7 7/10 0.22‡
Mean age (y) 66.3 (11.9) 62.7 (8.0) 64.3 (9.5) 0.49*
Time outside per day (in minutes) 146.8 (131.3) 319.5 (238.5) 245.6 (204.4) 0.01*
Max. walking time (in minutes) 57.5 (42.8) 119 (76.8) 116.0 (72.5) 0.01*
Disease duration (in years) 8.7 (6.4) 6.4 (3.7) - 0.17†
SPES Motor 11.8 (4.5) 8.5 (2.9) - 0.01†
SPES ADL 9.7 (2.8) 7.2 (2.7) - 0.01†
Levodopa use 18 (82%) 15 (75%) - 0.59‡
Dopamine agonist use 15 (68%) 14 (70%) - 0.90‡
Other PD medication 7 (32%) 8 (40%) - 0.58‡
NOTE. Values are mean SD,n, or percentage
*ANOVA, † t-tests and ‡ chi-square tests
Characteristics of the PD-unstable group
In the PD-unstable group the mean number of falls in the previous 6 months was 4.1 
per patient (range, 0-20). Fifteen of the 22 patients had experienced two or more falls. Most 
falls occurred outdoors. The mean number of times patients had to be caught and prevented a 
fall in the last 6 months was 1.5 (range 0-10). Almost half of the unstable patients used some 
sort of walking aid. Six patients took precautions to prevent falling, including rearranging 
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furniture, walking with caution, or no longer riding a bike. Two of these six patients had not 
experienced falls in the previous six months, but one had two near falls and the other used a 
walking aid.
Interrater reliability
For each rating procedure, the mean of the weighted κ was calculated for each pair 
of raters (Table 2). The agreement between the raters was high (>0.80) for most of the ratings. 
The highest interrater reliability was found for the rating of the steady stance positions (0.98) 
and the Pastor rating (0.98), whereas the lowest was found for the UPDRS (0.63).
Table 2: Interrater Reliability for the Ratings (weighted κ mean) per execution
Ratings according to: Execution 1 Execution 2
Nutt 0.93 0.84
Bloem 0.85 0.88
UPDRS 0.63 0.57
SPES 0.87 0.82
Pastor 0.98 0.96
Steady stance positions (right leg) 0.98 0.98
Steady stance positions (left leg) 0.97 0.98
Concurrent criterion validity
 ANOVA showed signiﬁcant differences between the three groups for all ratings 
on both executions, except for the second test of the right and left steady stance positions 
(Table 3). Using post hoc t tests to analyse differences between each combination of two 
groups, the PD-unstable group scored signiﬁcantly higher than the PD-stable group for the 
rating of the ﬁrst execution of each test, except for the rating of the right and left steady stance 
positions, in which no signiﬁcant differences were found. Compared with controls, the PD-
unstable group had signiﬁcantly higher values on all ratings for the ﬁrst execution, except for 
the Pastor rating, which had poor discriminative ability. For the ﬁrst execution of the tests, the 
PD-stable group did not differ signiﬁcantly from the control group, except for higher scores 
of the left steady stance positions.
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Table 3: Means and SDs for the two executions, in all subjects by group
Ratings according to: PD-unstable PD-stable Controls p*
First Execution
Nutt 0.82 (0.73) 0.12 (0.31) 0.33 (0.49) 0.00
Bloem 0.82 (0.66) 0.16 (0.34) 0.33 (0.49) 0.00
UPDRS 0.82 (0.75) 0.18 (0.24) 0.27 (0.14) 0.00
SPES 0.74 (0.69) 0.08 (0.25) 0.04 (0.12) 0.00
Pastor 1.06 (0.87) 0.40 (0.68) 0.67 (0.82) 0.03
Steady stance positions (right leg) 0.74 (0.94) 0.42 (0.90) 0.11 (0.30) 0.07
Steady stance positions (left leg) 1.00 (1.19) 0.39 (0.68) 0.0 (0.0) 0.00
Second Execution
Nutt 0.67 (0.56) 0.17 (0.37) 0.0 (0.0) 0.00
Bloem 0.67 (0.56) 0.19 (0.37) 0.0 (0.0) 0.00
UPDRS 0.68 (0.57) 0.18 (0.25) 0.20 (0.17) 0.00
SPES 0.61 (0.62) 0.08 (0.24) 0.04 (0.12) 0.00
Pastor 1.17 (0.98) 0.53 (0.82) 0.49 (0.63) 0.02
Steady stance positions (right leg) 0.57 (0.91) 0.47 (1.06) 0.07 (0.26) 0.20
Steady stance positions (left leg) 0.55 (1.05) 0.60 (0.88) 0.18 (0.53) 0.34
*Tested with Anova.
For the ratings of the second execution of each test, the PD-unstable group scored 
signiﬁcantly higher than the PD-stable group, except for the rating of the left and right steady 
stance positions. The PD-unstable group also had signiﬁcantly higher values than the control 
group on all ratings of the second execution except for the rating of the left steady stance 
positions. No signiﬁcant differences between the PD-stable group and the control group were 
found for the second execution, except for a higher scoring of the PD-stable group on the 
Bloem rating. In the PD-unstable group, the means of all the second executions were lower 
then those of the ﬁrst executions (except for the Pastor rating), but these differences were 
only signiﬁcant for the rating of the left steady stance positions.  
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Table 4: Sensitivity and speciﬁcity to classify patients as PD-stable and PD-unstable, 
the positive and negative predictive value and the overall predictive accuracy 
Ratings according to: Sensitivity/ Positive/Negative Overall predictive 
Speciﬁcity predictive value accuracy
First Execution 
Nutt 0.63/0.88 0.86/0.69 0.75
Bloem 0.65/0.85 0.83/0.69 0.74
UPDRS 0.66/0.82 0.83/0.67 0.71
SPES 0.55/0.92 0.88/0.65 0.72
Pastor 0.70/0.69 0.72/0.67 0.69
Steady stance positions (right leg) 0.45/0.79 0.71/0.56 0.61
Steady stance positions (left leg) 0.50/0.73 0.70/0.55 0.61
Second Execution
Nutt 0.59/0.82 0.79/0.65 0.71
Bloem 0.61/0.81 0.78/0.65 0.70
UPDRS 0.59/0.82 0.83/0.66 0.70
SPES 0.51/0.92 0.88/0.63 0.71
Pastor 0.65/0.69 0.71/0.64 0.67
Steady stance positions (right leg) 0.34/0.81 0.73/0.46 0.54
Steady stance positions (left leg) 0.26/0.61 0.46/0.39 0.41
Predictive criterion validity
For each rating procedure, the sensitivity and speciﬁcity, the positive and negative 
predictive value, and the overall predictive accuracy were calculated and averaged over 
the three raters (Table 4). The ﬁrst test execution of the Nutt rating had the highest sum of 
sensitivity and speciﬁcity (0.63 + 0.88 = 1.51), the highest sum of positive and negative 
predictive value (0.86 + 0.69 = 1.55) and hence the highest overall predictive accuracy (0.75) 
to correctly predict the patients in the PD-stable and PD-unstable groups. The area under the 
receiver operator curve for this rating was 0.80. The rating of the steady stance positions, 
both left and right sides, had the lowest overall predictive accuracy (both 0.61) and a very 
low sensitivity (0.50, 0.45, respectively).
The Pastor rating had the lowest speciﬁcity (0.69). If taking one step backward (score 
“1”) was also considered as a normal response, the speciﬁcity of the rating improved from 
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0.69 to 0.90, but this reduced the sensitivity to 0.33, and the overall predictive accuracy to 
0.61. For all ratings, the scoring of the ﬁrst test execution was the most informative, because 
the sum of sensitivity and speciﬁcity and the overall predictive accuracy was higher for all 
ﬁrst executions than for the second executions. 
Discussion
There is no gold standard for postural instability. Therefore, an external criterion like 
the number of falls in the previous six month is often used for validation. Two or more falls in 
the previous year is a good predictor of future falls,18 but it does not fully cover the content of 
postural stability. In our study, another external criterion was used that covered a more global 
concept of postural stability. This criterion included not only patients who had actually fallen, 
but also all individuals who were unstable and therefore at risk of falling. Taking into account 
the near falls and the adaptations patients made, intended to prevent falls, reduced the risk 
that unstable patients were inadvertently misclassiﬁed as non-fallers.19 This factor may have 
confounded the interpretation of previous studies and could explain why many balance tests 
failed to distinguish between subjects classiﬁed as fallers and non-fallers. 
The validity of our new criterion of being at risk or not at risk of falling is supported 
by the signiﬁcant differences found between the PD-stable and PD-unstable groups for ADL 
and motor function, time spent outdoors, and maximum walking time. This difference is 
not found between the PD-stable group and the control group. These ﬁndings support the 
hypothesis that patients who are at risk of falling tend to restrict their activities.20 
In our study, only single-item tests are included, because the aim was to include 
the best item in a motor scale. Therefore, multiple-item postural stability tests such as the 
Tinetti Balance Test of the Performance Oriented Assessment of Mobility Problems21 or the 
Berg Balance Scale22 were excluded from the study design. For similar reasons, no tests were 
included that required speciﬁc equipment (eg, rulers, dense foam), needed extra personnel 
(eg, for a sternum push, to support subjects in case of an imminent fall), or that could only be 
performed in a movement laboratory (eg, posturography). Although in previous studies both 
the Tinetti Balance Test and posturography tests23 poorly predicted falls in daily life, we still 
must consider whether multiple-item or laboratory postural stability tests may better predict 
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the abilities of patients to remain stable or unstable. However, these tests do not ﬁt our criteria 
of a simple, clinical, single-item test for postural stability.
The results of our study suggest that postural stability in patients with PD is best 
evaluated with the retropulsion test as recommended by Nutt et all.12 This variant of the 
retropulsion test is based on an unexpected shoulder pull. Taking more than two corrective 
steps is regarded as an abnormal test result. The interrater reliability is high (weighted κ mean 
= 0.93) and, compared with the other balance tests, the validity is high with a sensitivity 
of 0.63, a speciﬁcity of 0.88, a positive predictive value of 0.86, a negative predictive 
value of 0.69, and an overall predictive accuracy of 0.75. The postural reaction to the ﬁrst 
shoulder pull had a better classiﬁcation rate than the reaction to the second shoulder pull. 
This difference is possibly the result to a confounding effect of habituation or motor learning 
across consecutive tests.24
The Bloem rating is based on an unexpected shoulder pull as well. This variant of 
the retropulsion test also takes into account the speed at which patients restore their balance. 
This modiﬁcation is theoretically attractive because unstable patients may take only few 
corrective steps backward yet restore their balance in a very slow and clearly abnormal 
manner. However, scoring the speed of recovery did not improve the diagnostic accuracy, 
over and above the clinimetric properties of the Nutt rating. Moreover, even though interrater 
reliability for the Bloem rating was fair in this study, we suspect that evaluating the speed 
with which balance is restored, is susceptible to subjective factors, making this variant 
theoretically less reliable.
In agreement with other studies,25 our results show that unexpected shoulder pulls 
are a better predictor of postural stability than expected shoulder pulls. Moreover, our results 
suggest that the ﬁrst trial is the most informative. These results are probably explained by the 
fact that unpredictable and unpractised balance tests better reﬂect situations in every day life, 
when people have to react to sudden, unexpected changes in their environment.
The postural stability item of the UPDRS has the lowest interrater reliability. Other 
studies,26;27 however, have found a higher reliability. The lower interrater agreement in our 
study may be explained by the more subjective aspect in the response options of postural 
stability in the UPDRS: normal or retropulsion, but recovers unaided. It is unclear how many 
corrective steps are still regarded as normal, and when retropulsion is considered present. In 
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other ratings of pull tests, a clear description of the precise number of steps taken backwards 
is included in the response options. 
The rating as described by Pastor and colleagues has objective and distinct response 
options and is therefore very easy to score. This results in a very high interrater reliability 
(weighted κ mean = 0.96). However, the validity and especially the speciﬁcity of the scale are 
low. Apparently, an abnormal score is easily given, even to stable PD patients and controls. 
Adjusting the score for a normal and deviant response does not improve the predictive 
abilities of the test.
Shoulder pulls are seemingly simple tests, but considerable problems arise because 
the test circumstances are difﬁcult to standardize. Both between and within examiners the pull 
force may vary, and between subjects of different height and weight the pull force required 
to disturb the balance will also differ.28 We therefore included the steady-stance positions, 
because this could be standardized more easily because of absence of an external balance 
perturbation. The interrater reliability of these steady-stance positions was indeed excellent 
(weighted κ mean = 0.98) and scoring was straightforward. However, the validity of this 
scale is poor, and the sensitivity especially is low. Surprisingly, the positions are easy to 
maintain, even for unstable PD patients. The rating of the steady-stance positions is therefore 
not able to differentiate between the PD-stable, PD-unstable and control groups. Apparently, 
maintaining static balance in positions with a successive decrease in supporting surface does 
not correspond adequately with being at risk of falling in everyday life. 
In our study, of 42 consecutive subjects with PD from an outpatient movement 
disorders clinic, more than half of the patients indicated to be in some way at risk for falling 
in daily life, whereas ﬁfteen patients have actually experienced two or more falls during the 
last six months. Both the frequency of postural instability in patients with PD and the severity 
of the accompanying problems indicate that regular, clinical testing is important.
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Conclusion
The most valid test condition of postural instability in PD is an unexpected shoulder 
pull, executed once, with taking more than two corrective steps backwards in response to the 
disturbance considered as deviant. The rating of the retropulsion test, as executed and scored 
according to Nutt, fulﬁls these requirements, has a good interrater reliability, and can easily 
be used to test for postural stability in PD in a clinical setting.12 
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Appendix
Ratings (and the accompanying test condition):
1. Nutt (Shoulder pull, unexpected) 
0 = normal, may take 2 steps to recover
1 = takes 3 or more steps; recovers unaided
2 = would fall if not caught
3 = spontaneous tendency to fall or unable to stand unaided (test not executable).
2. Bloem (Shoulder pull, unexpected)
0 = normal, quick recovery of balance, may take up to 2 steps to recover
1 = takes 3 or more steps to recover, or restores balance slowly; recovers unaided
2 = would fall if not caught
3 = spontaneous tendency to fall or unable to stand unaided (test not executable)
3. UPDRS (Shoulder pull, expected)
0 = normal
1 = retropulsion, but recovers unaided
2 = absence of postural response, would fall if not caught by examiner
3 = very unstable, tens to lose balance spontaneously
4 = unable to stand without assistance
4. SPES (Shoulder pull, expected)
0 = normal, may take 2 steps to recover
1 = retropulsion but recovers unaided
2 = retropulsion, but will fall if unaided
3 = unable to stand unaided
5. Pastor (Shoulder pull, expected, and subject instructed not to step backwards)
0 = subject stays upright without taking a step
1 = takes one step backward but remains steady
2 = takes more than 1 step backwards but remains steady
3 = one or more steps backward, but needs to be caught
4 = falls backward without an attempt to step
6. Steady stance positions (separately for right and left leg) (two leg stance, tandem stance, 
 single leg stance, single leg stance with the hands raised above the head)
0 = single leg stance with the hands raised above the head for more than 5 seconds
1 = single leg stance for more than 5 seconds
2 = tandem stance for more than 5 seconds
3 = two leg stance for more than 5 seconds 
4 = not able to perform two leg stance for more than 5 seconds
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Abstract
Objectives: To evaluate the reliability and validity of the Short Parkinson’s Evaluation Scale 
(SPES)/SCales for Outcomes in PArkinson’s disease (SCOPA), a short scale developed to 
assess motor function in patients with Parkinson’s disease (PD). 
Methods: Eighty-ﬁve patients with PD were assessed with the SPES/SCOPA, Uniﬁed 
Parkinson’s Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) scale, and Schwab and 
England (S&E) scale. Thirty four patients were examined twice by two different assessors 
who were blinded to each other’s scores and test executions. Additionally, six items of the 
motor section of the SPES/SCOPA were assessed in nine patients and recorded on videotape, 
to evaluate inter-rater and intra-rater reliability. 
Results: The reproducibility of the sum scores in the clinical assessments was high for all 
subscales of the SPES/SCOPA. Inter-rater reliability coefﬁcients for individual items ranged 
from 0.27-0.83 in the motor impairment section, from 0.58-0.82 in the activities of daily 
living section, and from 0.65-0.92 in the motor complications section. Inter-rater reliability 
of the motor items in the video assessments ranged from 0.70-0.87 and intra-rater reliability 
from 0.81-0.95. The correlation between related subscales of the SPES/SCOPA and UPDRS 
were all higher than 0.85, and both scales revealed similar correlations with other measures 
of disease severity. The mean time to complete the scales differed signiﬁcantly  (p<0.001) 
and measured 8.1 (SD 1.9) minutes for the SPES/SCOPA and 15.6 (SD 3.6) minutes for the 
UPDRS. 
Conclusion: The SPES/SCOPA is a short, reliable, and valid scale that can adequately be 
used in both research and clinical practice.
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Over the past 15 years the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) has 
become a standard tool in the clinical evaluation of patients with Parkinson’s Disease (PD). 
The UPDRS is the most frequently used scale in PD trials1 and has acceptable inter-rater and 
intra-rater reliability for most items.2 3 The construct validity with other scales is adequate but 
the content validity has been questioned, especially with respect to its conceptual clearness 
and balance between items that represent symptoms responsive to dopaminergic treatment 
and those more resistant to this intervention.2 Other critiques include the length of the scale4 
and the redundancy of items.5 The mean time to complete the scale is approximately 17 
minutes for experienced users,4 which makes it less suitable for clinical application. Van 
Hilten et al5 demonstrated that the UPDRS can be shortened by removing redundant items 
from the motor section and conceptually unclear items from the activities of daily living 
(ADL) section, without negative consequences for reliability or validity. A shorter scale with 
similar clinimetric properties may have advantages for patients, clinicians, and researchers. 
As a result of the aforementioned considerations, the Short Parkinson’s Evaluation 
Scale (SPES) was developed.6 The scale is short, conceptually clear, and displays good 
reliability and validity.2 The instrument is considered easy to use by its evaluators6 but has 
only been used in a few studies.7-10
Careful inspection of the SPES, however, indicates that the consistency in the framing 
of response options may be improved. The item ‘swallowing’ represents an impairment and 
should be moved from the disability (ADL) section to the motor impairment (MI) section 
in order to be consistent with current methodological concepts of scale construction.11 12 
Additionally, some clinimetric aspects of the SPES have not been addressed to date. These 
aspects involve intra-rater and inter-rater reliability between two assessors who perform 
the clinical assessments separately. Hence, we ﬁrst modiﬁed the SPES according to the 
aforementioned considerations and subsequently evaluated this scale, the SPES/SCOPA. 
The development of this scale is part of a larger research project on SCales for Outcomes in 
PArkinson’s disease (SCOPA)13 in which short, practical, and clinimetric sound scales for all 
relevant domains in PD are selected or developed.The objective of this study was to evaluate 
the reliability (intra-rater and inter-rater reliability, internal consistency) and construct validity 
(correlation with related scales, ‘known-groups’ comparisons) of the SPES/SCOPA. 
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Methods 
Development of the SPES/SCOPA
The SPES/SCOPA consists of three sections: MI, ADL, and motor complications 
(MC). There are four response options, ranging from 0 (normal) to 3 (severe). In comparison 
with the original SPES, some modiﬁcations to the three sections were made based on ﬁndings 
in the literature and empirical testing of some of the items. The mental section was removed 
altogether, because we felt that these important functions could not be assessed in a reliable 
and valid way by a few single questions; as a part of the SCOPA project, we tested and 
developed separate instruments for these functions.13 
Motor impairments 
Tremor. Pooled data of several studies8 14-17 (total 1361 patients) revealed that in 
less than 4% of the patients the tremor score of the legs was higher than that of the arms, 
and that in only 2% of the patients a tremor in the legs was present while it was absent in 
the arms. For reasons of efﬁciency, we therefore decided to evaluate tremor in the upper 
extremities only. Additionally, in the response options we linked the amplitude of the tremor 
to a displacement in centimetres to improve the quantiﬁcation of ‘small’, ‘moderate’, and 
‘severe’. Bradykinesia. ‘Finger tapping’ was replaced by ‘rapid alternating movements’ on 
the basis of the results of a separate study in which we compared ﬁve different tests for 
bradykinesia.18 This study revealed that this test had the highest intra-rater and inter-rater 
reliability and the highest correlation with measures of disease severity. Both tremor and 
bradykinesia were assessed during 20 seconds. A time window was not indicated in the 
original SPES. Rigidity. The phrase ‘detectable only on activation of the contralateral arm’ 
was removed from the response options, because a pilot study showed that the muscle tone 
in the ipsilateral arm also increased in many healthy individuals if the contralateral arm 
was raised. Rigidity was now evaluated by ‘perceived difﬁculty in trying to reach the end 
positions in elbow or wrist’, which proved to be a useful criterion in a pilot study we held 
in 17 patients with PD. Postural stability. This item was modiﬁed on the basis of a study, in 
which we compared six tests for postural stability.19 The word ‘retropulsion’ was removed 
from the response options, and the scoring was now determined by the number of steps 
patients took to restore balance and by whether a patient would fall or not. Arising from chair, 
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gait and speech. These items only underwent minimal changes compared with the original 
SPES and do not need detailed discussion. Two other impairments were added and evaluated 
historically, namely, swallowing and freezing during ‘on’. We considered it more important 
to assign items to the appropriate section, than to assign items to sections on the basis of the 
way they are elicited (examination versus history). ‘Swallowing’ was therefore moved from 
the ADL section to the MI section. ‘Freezing during on’ was added because it was considered 
a useful progression marker of PD that is less responsive to dopaminergic interventions. We 
expected to achieve a better balance between the more dopamine-responsive and the more 
dopamine-resistant features if this item was added. The maximum score in the MI section is 
42.
Activities of daily living 
The response options were framed as uniformly as possible. Responses reﬂected no 
difﬁculty (normal), some difﬁculty (no assistance needed), considerable difﬁculty (possibly 
needing assistance), and unable (or needing complete or almost complete assistance). As 
stated before, ‘swallowing’ (previously addressed under ‘eating’) was removed. ‘Turning and 
getting out of bed’, was extended to ‘changing positions’, to include all important transfers of 
daily life. The maximum score in this section is 21.
Motor complications 
The original section on complications of therapy was modiﬁed and now evaluated 
both the presence and severity of dyskinesias and motor ﬂuctuations. Freezing and dystonia 
were removed, because these phenomena cannot solely be attributed to dopaminergic treatment 
and, hence, may not reﬂect complications of treatment. Additionally, in patients treated with 
levodopa, dystonia may emerge while patients are ‘on’ or ‘off’ or during the switch of one 
state to the other and coincide with other dyskinesias. In view of this complexity and the 
fact that ‘off’ and dyskinesias are already assessed, we decided not to evaluate dystonia 
separately. Items were framed to address the impairment level. The maximum score is 6 for 
the dyskinesia section and 6 for the motor ﬂuctuations section.
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Patients
Eighty-ﬁve consecutive, non-demented patients who visited the outpatient clinic of 
the Department of Neurology of the Leiden University Medical Center, and who fulﬁlled the 
United Kingdom Parkinson’s Disease Society Brain Bank criteria for idiopathic PD,20 were 
included in the clinical assessments. Patients were excluded if they also had other diseases of 
the central nervous system or were not able to understand Dutch. Nine patients that met the 
same eligibility criteria were included in video assessments. The study was approved by the 
medical ethics committee of the Leiden University Medical Center.
Assessment procedures
The patients were evaluated with the SPES/SCOPA (appendix), UPDRS parts II 
- IV,21 the Hoehn and Yahr (H&Y) scale,22 and the Schwab and England (S&E) scale.23 The 
latter three scales were included to evaluate the construct validity of the SPES/SCOPA. One 
global question evaluated overall ADL functioning and patients were asked to indicate on a 
seven-point-scale (ranging from very good to very bad) how well they were able to carry out 
various daily activities in the past month. Patients also indicated whether they were ‘on’ or 
‘off’ at the time of assessment. Additional information gathered involved medication, disease 
duration, and comorbidity. 
Reproducibility of the SPES/SCOPA was assessed in three different ways: inter-
rater reliability of clinical assessments, inter-rater reliability of video assessments, and 
intra-rater reliability of video assessments. In the clinical assessments, 34 patients were 
assessed twice by the investigators (JM, MV), who assessed patients separately in immediate 
succession and were blind to each other’s scores and test executions. Reproducibility was 
calculated in patients with a stable response to medication during this period – that is, who 
had no ‘on-off’ transitions. In the video assessments, inter-rater reliability was assessed by an 
international panel of movement disorders specialists (from Italy, Israel, Spain, Germany, and 
The Netherlands) who rated nine videotaped patients with a stable response to medication 
during the time the recordings were made. This panel rated the videotaped patients twice 
with an interval of 7-14 days. In the video recordings, six items from the MI section were 
presented. The other four items of this section were not appropriate for video scoring- that 
is, rigidity, speech, and the two historic items. Rigidity could not be evaluated from video 
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for obvious reasons, and the other three items were not included because patients and raters 
spoke different languages. 
Statistical analysis
Reproducibility was assessed with the intra-class correlation coefﬁcient (ICC; one-
way random effects model) if two ratings were compared (inter-rater reliability in clinical 
assessments and intra-rater reliability in video assessments), and with Kendall’s coefﬁcient 
of concordance W if it concerned agreement between more than two raters (inter-rater 
reliability in video assessments). The ICC is equivalent to the weighted kappa if quadratic 
weights are used.24 We therefore used the ‘strength-of-agreement’ classiﬁcation as proposed 
by Landis and Koch,25 who classiﬁed strength of agreement as slight (0.00-0.20), fair (0.21-
0.40), moderate (0.41-0.60), substantial (0.61-0.80), or almost perfect (0.81-1.00). Internal 
consistency of subscales was evaluated with Cronbach’s alpha. Construct validity was 
evaluated by determining the correlation between scales, using Pearson’s r for the correlation 
of SPES/SCOPA with UPDRS and S&E, and Spearman’s test r
s
 for the correlation with H&Y 
and ‘global functioning’. ‘Known-groups’ validity was assessed by comparing scores of 
patients with different disease severity -that is, by H&Y, using analysis of variance (ANOVA) 
and ordinal regression.
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Results
The characteristics of patients that participated in the clinical assessment are 
presented in table 1. The ﬁve men and four women recorded on video had a mean age of 62.4 
years and a mean disease duration of 12.4 years. Three of these patients were in H&Y stage 
2, three in H&Y 3, and three in H&Y 4 (data not shown). 
Table 1: Patient characteristics
number of patients 85
mean (SD) age (years) 65.4 (10.4)
number (%) males 52 (61.2%)
mean (SD) disease duration (years) 10.5 (5.8)
Hoehn & Yahr stages: 
 1 0
 2 25
 3 42
 4 18
 5 0
mean (SD) SPES/SCOPA-Motor impairments 13.8 (5.1)
mean (SD) SPES/SCOPA-ADL 8.5 (3.2)
mean (SD) UPDRS-Motor evaluation 32.6 (10.9)
mean (SD) UPDRS-ADL 15.9 (6.0)
mean (SD) Schwab & England 75.7 (12.4)
n assessed while ‘on’ / ‘off’ / missing 78 / 5 / 2
n (%) on levodopa 72 (84.7%)
mean (SD) levodopa dose in users (mg) 535 (407)
n (%) on dopamine agonists 63 (74.1%)
Practicality 
The mean time necessary to complete the scales was 8.1 (SD 1.9) minutes for the 
SPES/SCOPA and 15.6 (SD 3.6) minutes for the UPDRS. This difference was signiﬁcant 
(p<0.001).
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Table 2: Inter-rater reliability (ICC) of motor impairment items in clinical assessment
Shared items SPES/SCOPA UPDRS Non-shared items
Rest tremor R 0.63 0.53
Rest tremor L 0.67 0.45
Postural tremor R 0.34* 0.34*
Postural tremor L 0.64 0.58
Rapid alternating mov. R 0.58 0.59
Rapid alternating mov. L 0.45 0.50
Rigidity R 0.27* 0.38*
Rigidity L 0.61 0.64
Rise from chair 0.83 0.83
Postural instability 0.60 0.59
Gait 0.60 0.63
Speech 0.55 0.68
0.57 Freezing in ‘on’
0.79 Swallowing
0.36* Facial expression
0.21* Rest tremor head
0.00** Rest tremor R leg
0.00** Rest tremor L leg
0.59  Rigidity head
0.29* Rigidity R leg
0.44 Rigidity L Leg
0.46 Finger tap R
0.39* Finger tap L
0.28* Hand movements R
0.67 Hand movements L
0.53 Leg agility R
0.61 Leg agility L
0.66 Posture
0.23* Body bradykinesia
* all agreements at least ‘moderate’ (>0.40), except *, where agreement is fair (ICC = 0.21-0.40)25
** estimates unreliable (insufﬁcient dispersion); % agreement 97.1 (R leg) and 91.2 (L leg)
NB: 8 items in UPDRS (U) and 2 items in SPES/SCOPA (S) with poor agreement (≤ 0.40)
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Reliability of clinical assessments
 One patient changed from ‘on’ to ‘off’ between both clinical assessments and was 
removed from the analysis; hence, inter-rater reliability was hence assessed in 33 patients. 
The inter-rater reliability coefﬁcients for the motor sections of the clinical assessments were 
all at least  ‘moderate’ according to the Landis & Koch criteria, except for two items in 
the SPES/SCOPA (‘postural tremor right hand’, ‘rigidity right arm’) and eight items in the 
UPDRS (table 2). The latter eight items also included the two items that had ‘fair’ reliability 
in the SPES/SCOPA. The mean reliability coefﬁcient calculated over the items that were 
shared by both scales, was 0.56 for both. The mean ICC calculated over all the items of the 
motor sections was 0.58 for the SPES/SCOPA and 0.50 for the UPDRS.
 
Table 3:  Inter-rater reliability (ICC) of ADL items in clinical assessment
Shared items SPES/SCOPA UPDRS Non-shared items
Speech 0.66 0.68
Feeding 0.63 0.61
Dressing 0.80 0.76
Hygiene 0.70 0.71
Changing positions 0.58* 0.73
Walking 0.61 0.66
Handwriting 0.82 0.85
0.91 Salivation
0.90 Swallowing
0.73 Falling (unrelated to freezing)
0.77 Freezing when walking
0.83 Tremor
0.68 Sensory complaints
* all agreements ‘substantial’ (> 0.60), except changing positions (S15), where agreement is ‘moderate’
Two items in the UPDRS (rest tremor left and right leg) could not reliably 
be calculated as a result of insufﬁcient dispersion; however, percentage agreement for 
these items was high (table 2). Results for the ADL section are presented in table 3. All 
agreements were at least ‘substantial’, except ‘changing positions’ in the SPES/SCOPA.  
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The mean reliability coefﬁcient calculated over the shared items of the ADL sections was 
0.69 for the SPES/SCOPA and 0.71 for the UPDRS. The mean ICC over all items of the ADL 
section of the UPDRS was 0.76. 
Table 4: Inter-rater reliability (ICC) of motor complication items in clinical assessment
Shared items SPES/SCOPA UPDRS Non-shared items
Dyskinesias
Presence dyskinesias 0.92 0.96
0.74 Severity dyskinesias
0.94 How disabling dyskinesias?
0.71 How painful dyskinesias?
0.39* Early morning dystonia?
Motor Fluctuations
Presence ‘off’ periods 0.69 0.65
0.65 Severity ‘off’ periods
0.71 Off periods predictable?
0.41** Off periods unpredictable?
0.62 Sudden offs?
NB: all agreements ‘substantial’, except for * U35 (‘fair’) and ** U37 (‘moderate’)
The motor complication sections of both scales (table 4) shared only one item in 
both the dyskinesia and the motor ﬂuctuation section. The mean ICC for the items in the 
dyskinesia section was 0.83 for the SPES/SCOPA and 0.75 for the UPDRS. The mean ICC 
for items in the motor ﬂuctuation sections was 0.67 for the SPES/SCOPA and 0.60 for the 
UPDRS. The ICCs of the sumscores of the UPDRS were generally higher than those of the 
SPES/SCOPA (table 5).
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Reliability of video assessments
The inter-rater reliability coefﬁcients for the items in the video assessments were 
0.70 or higher and therefore all at least ‘substantial’ (table 6). Intra-rater reliability coefﬁcients 
were higher, with all items above 0.80 (‘almost perfect’).
Internal consistency
The internal consistencies of the SPES/SCOPA scales were higher than those of 
the UPDRS, except for the MI scale (table 5). ‘Sensory symptoms’ in the UPDRS-ADL had 
a negative corrected item-total correlation (-0.02). Other items with corrected correlations 
below 0.20 involved rest tremor of the right hand (0.15) and swallowing (0.18) in the SPES/
SCOPA, and rest tremor of head, right hand, left hand, and right leg (0.03, 0.11, 0.16, and 
0.18, respectively) in the UPDRS motor section, and tremor (0.05) in the UPDRS ADL 
section. The corrected item-total correlation of the tremor of the left hand was considerably 
higher in both scales (0.40 in the SPES/SCOPA and 0.31 in the UPDRS).
Table 5: Inter-rater reliability and internal consistency of SPES/SCOPA and UPDRS 
ICC sumscores ICC items Cronbach α item-total1
SPES/SCOPA Motor 0.86 0.27 - 0.83 0.74 0.15 – 0.65
UPDRS Motor 0.90 0.002 - 0.83 0.88 0.03 – 0.65
SPES/SCOPA ADL 0.89 0.58 - 0.82 0.81 0.38 – 0.72
UPDRS ADL 0.93 0.61 - 0.91 0.75 -0.023 – 0.65
SPES/SCOPA Dyskinesias 0.89 0.74 – 0.92 0.92 NA4
UPDRS Dyskinesias 0.94 0.39 - 0.96 0.58 0.11 - 0.63
SPES/SCOPA Fluctuations 0.72 0.65 – 0.69 0.95 NA4
UPDRS Fluctuations 0.75 0.41 – 0.71 0.74 0.48 - 0.66
NB: Values obtained by clinical assessment in 85 patients. 1 corrected item-total correlation; 2 tremor R and L 
leg; estimates unreliable due to insufﬁcient dispersion; 3 sensory symptoms; 4 not applicable (only two items)
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Table 6: Reliability of SPES/SCOPA  items assessed by video
intra-rater1 inter-rater2
rest tremor R 0.95 0.83
rest tremor L 0.87 0.71
postural tremor R 0.91 0.71
postural tremor L 0.93 0.87
rapid alt mov R 0.86 0.80
rapid alt mov L 0.81 0.70
rise from chair 0.86 0.72
postural instability 0.87 0.87
gait 0.84 0.70
1 assessed by weighted kappa (quadratic weights); 14 raters 
2 assessed by Kendall’s coefﬁcient of concordance W; 14 raters
Validity
Correlations between related sections of the SPES/SCOPA and the UPDRS were 
0.88 for MI, 0.86 for ADL, 0.86 for dyskinesias, and 0.95 for motor ﬂuctuations. The 
correlations of these sections with the H&Y and S&E scale were all similar: all differences 
in correlations in a range between 0.02 and 0.10. The correlation between these sections and 
disease duration also bore strong resemblance, with coefﬁcients of 0.38 (SPES/SCOPA) and 
0.23 (UPDRS) for the motor sections, and 0.29 (SPES/SCOPA) and 0.36 (UPDRS) for the 
ADL sections. The correlation with global ADL functioning was 0.49 for the SPES/SCOPA 
ADL and 0.48 for the UPDRS ADL.
Mean scores of patients grouped by their H&Y stages (table 7) indicated signiﬁcant 
differences between groups for both the motor and ADL sections of both scales (ANOVA; 
all p-values < 0.001). Post-hoc t tests showed no signiﬁcant differences between patients in 
H&Y 2 and H&Y 3 in both scales, but differences between stages 2 and 4, and between stages 
3 and 4, were signiﬁcant. A signiﬁcant trend was present in both sections of the scales, with 
higher scores for patients with more advanced PD.
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Table 7:  Scale scores grouped by Hoehn and Yahr stages (‘known-groups’ comparisons)
Hoehn & Yahr ANOVA post-hoc t-tests ordinal regression
2 3 4 2-3 3-4 2-4 trend2 ﬁt3 R-sq4
SPES/SCOPA 11.1 13.4 18.7 <0.001 0.11 <0.001 <0.001 <0.001 0.57 0.26
motor
UPDRS motor 27.7 31.0 43.1 <0.001 0.51 <0.001 <0.001 <0.001 0.78 0.25
SPES/SCOPA 7.2 7.9 11.8 <0.001 0.84 <0.001 <0.001 <0.001 0.33 0.30
ADL
UPDRS ADL 13.4 15.0 21.6 <0.001 0.72 <0.001 <0.001 <0.001 0.44 0.26
1numbers in the columns are p-values of differences in scores of patients in different Hoehn and Yahr stages
2a signiﬁcant trend indicates that the trend differs signiﬁcant from zero (i.e., no trend)
3goodness of ﬁt: p > 0.05 indicates that the model does not differ signiﬁcantly from a model with a good ﬁt
4R-square: proportion of the variance accounted for by the model.
Discussion
We evaluated several aspects of the clinimetric performance of the SPES/SCOPA. 
Inter-rater reliability and internal consistency obtained by clinical assessment among 85 
patients were very similar for the SPES/SCOPA and the UPDRS. The reproducibility of 
the sumscores of the SPES/SCOPA was high. Two items in the motor section displayed less 
than moderate agreement- that is, both  ‘postural tremor’ and ‘rigidity’ of the right arm. The 
same items on the same side also performed only fairly in the UPDRS, and previous studies 
on the UPDRS have also found lower scores for these items.4 26 27 Inter-rater reliability of 
the SPES/SCOPA MI section assessed from video displayed higher scores than the clinical 
assessments, with all values above 0.70. Intra-rater reliability is even higher, with all 
reliability coefﬁcients over 0.80. Items in the ADL section were only evaluated in the clinical 
assessment situation, and all displayed at least ‘substantial agreement’, with the exception 
of ‘changing positions’. Items in the motor complication section all showed ‘substantial’ 
reproducibility. The results from our study comply with previous ﬁndings in which the SPES 
and UPDRS were compared,6 with comparable items displaying similar reliability. The 
internal consistency of all SPES/SCOPA scales was above 0.70, which is considered the 
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minimum for group comparisons.28 
The correlation between related SPES/SCOPA and UPDRS sections is high, which 
is not surprising given the shared components of both scales. Additionally, the similarity of 
the correlations between the SPES/SCOPA and UPDRS compared with measures of disease 
severity, such as H&Y, S&E, global ADL functioning, and disease duration, is striking. This 
endorses the impression that the scales capture the same phenomena. Differences between 
patients grouped by their H&Y stages also display very similar results for both scales. 
Although the SPES/SCOPA contains only half the number of items and has four response 
options instead of ﬁve, reliability and validity are apparently preserved.
Inter-rater reliability in our study was generally lower than that seen in other studies. 
This is not surprising given that most previous studies used either video recordings, or a 
design where several raters assessed patients simultaneously, therewith excluding potential 
biases caused by changes in the patient’s state and differences in test executions. Video 
assessments are useful since they provide information on reproducibility in standardised 
situations and thus presenting the opportunity to locate weaker items that may beneﬁt from 
clearer instructions and descriptions. However, knowledge on the degree of reliability if 
patients are assessed at separate occasions, either by the same or different assessors, provides 
additional information because it reﬂects the routine of studies and clinical practice. To 
the best of our knowledge, only one study assessed the reproducibility of the UPDRS over 
separate clinical examinations.3 Because this study evaluated intra-rater reliability over a 
two-week interval, whereas we have assessed inter-rater reliability in immediate succession, 
the different designs do not allow a direct comparison. 
Future studies that aim to improve the performance of the items with lower reliability 
(postural tremor right, rapid alternating movements left, rigidity right) are recommended. 
postural tremor and rapid alternating movements may beneﬁt from a shorter time window. 
The longer the assessment time the greater chance that the performance becomes inconsistent 
(‘destabilises’). Another point that may improve the reliability is to state more clearly that 
the response option that best reﬂect the patient’s performance should be scored. Some raters 
may be in doubt whether to rate the best, worst, or mean performance. A shorter assessment 
period an clear instructions may be helpful. Whether these considerations will indeed be 
helpful must ﬁrst be assessed. Special attention must be paid to whether an improvement in 
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reliability is not obtained at the expense of validity, as some problems become apparent after 
longer performance.
Improving the item on rigidity will probably be difﬁcult. One possibility is to assess 
whether higher reliability can be obtained if rigidity is assessed separately for either th wrist 
or the elbow instead of a combination of both. 
It is unfortunate that we did not include more patients in the more extreme stages- 
that is, H&Y stages 1 and 5. It is difﬁcult to indicate whether our results can be extrapolated to 
patients in the end ranges, but it is usually more difﬁcult to rate the intermediate states (mildly, 
moderately affected) than the more extreme ones (normal, severely affected). More variation 
in the severity of the patients would probably have resulted in larger differences between 
individuals and, hence, in a larger between-subject variance. As the ICC is calculated as the 
ratio of the variance of true differences between individuals to the total variance this probably 
would have resulted in a higher ICC, which would indicate that our ﬁndings probably rather 
underestimate than overestimate the results.
To summarise, the SPES/SCOPA is a reliable, valid, and conceptually clear scale 
that is completed in half the time it takes to administer the UPDRS. These advantages may 
favour the use of the SPES/SCOPA in evaluating motor function in patients with PD.
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Appendix - SPES/SCOPA scale
A.    Motor evaluation
Clinical examination
  1. Rest tremor 
assess each arm separately during 20 seconds; hands rest on thighs; if tremor is not evident at 
rest, try to keep the patient attentive, e.g. by having him/her count backwards with eyes closed
         0 =     absent
         1 =     small amplitude (< 1 cm) occurring spontaneously, or obtained only while keeping 
        patient attentive (any amplitude)
         2 =  moderate amplitude (1-4 cm), occurring spontaneously
         3 =  large amplitude (≥ 4 cm), occurring spontaneously.
   2. Postural tremor 
check with arms outstretched, pronated and semipronated, and with index ﬁngers of both hands 
almost touching each other (elbows ﬂexed); assess each position during 20 seconds
 0 =  absent 
 1 = small amplitude (< 1cm)
 2 =  moderate amplitude (1-4 cm)
 3 =  large amplitude (≥ 4 cm).
  3. Rapid alternating movements of hands 
rapid alternating pronation/supination movements of upper hand, each time slapping the palm 
of the horizontally held lower hand during 20 seconds; each hand separately 
0 =  normal
1 =  slow execution, or mild slowing and/or reduction in amplitude; may have occasional 
arrests
2 =  moderate slowing and/or reduction in amplitude or hesitations in initiating movements or 
frequent arrests in ongoing movements
3 =  can barely perform task.
  4. Rigidity 
assess passive movements of elbow and wrist over full range, with the patient relaxed in sitting 
position; ignore cogwheeling; check each arm separately
 0 =  absent
 1 = mild rigidity over full range, no difﬁculty reaching end positions 
2 =  moderate rigidity, some difﬁculties reaching end positions
 3 =  severe rigidity, considerable difﬁculties reaching end positions.
   5. Rise from chair 
 patient is instructed to fold arms across chest; use straight back chair
 0 =  normal
 1 =  slowly; does not need arms to get up
 2 =  needs arms to get up (can get up without help)
 3 =  unable to rise (without help).
MOTOR IMPAIRMENTS AND DISABILITIES
52
  6. Postural stability 
 stand behind the patient and pull patient backwards, while s/he is standing erect with eyes open 
and feet spaced slightly apart; patient is not prepared
 0 =  normal, may take up to 2 steps to recover
 1 =  takes 3 or more steps; recovers unaided
 2 =  would fall if not caught
 3 =  spontaneous tendency to fall or unable to stand unaided.
  
7. Gait 
assess gait pattern; use walking aid or offer assistance, if necessary
 0 =  normal
 1 =  mild slowing and/or reduction of step height or length; does not shufﬂe
2 =  severe slowing, or shufﬂes or has festination
3 =  unable to walk.
   8. Speech 
 0 =  normal
 1 =  slight loss of expression, diction and/or volume
 2 =  slurred; not always intelligible
 3 =  unintelligible always or most of the time.
Historical information
  9. Freezing during ‘on’
Freezing is characterized by hesitation when trying to start walking or ‘gluing’ to the ground 
while walking.
0 =  absent
1 =  start hesitation only, occasionally present
2 =  frequently present, may have freezing when walking
3 =  severe freezing when walking.
10. Swallowing
 0 =  normal
 1 =  some difﬁculty or slow; does not choke; normal diet
 2 =  sometimes chokes; may require soft food
 3 =  chokes frequently; may require soft food or alternative method of food intake.
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B.  Activities of Daily Living
11. Speech
 0 =  normal
 1 =  some difﬁculty; may sometimes be asked to repeat sentences
 2 =  considerable difﬁculty; frequently asked to repeat sentences
 3 =  unintelligible most of the time. 
12. Feeding (cutting, ﬁlling cup, etc.)
 0 =  normal
 1 =  some difﬁculty or slow; does not need assistance 
 2 =  considerable difﬁculty; may need some assistance
 3 =  needs almost complete or complete assistance.
13. Dressing
 0 = normal
 1 = some difﬁculty or slow; does not need assistance
 2 = considerable difﬁculty; may need some assistance (e.g. buttoning, getting arms into
  sleeves)
 3 = needs almost complete or complete assistance.
14. Hygiene (washing, combing hair, shaving, brushing teeth, using toilet)
 0 = normal
 1 = some difﬁculty or slow; does not need assistance
 2 = considerable difﬁculty; may need some assistance
 3 = needs almost complete or complete assistance.
15. Changing position (turning over in bed, getting up out of bed, getting up out of a chair, 
turning around when standing)
 0 = normal
 1 = some difﬁculty or slow; does not need assistance with any change of position
 2 = considerable difﬁculty; may need assistance with one or more changes of position
 3 = needs almost complete or complete assistance with one or more changes of position.
16. Walking
 0 =  normal
 1 = some difﬁculty or slow; does not need assistance or walking aid
 2 = considerable difﬁculty; may need assistance or walking aid
 3 = unable to walk, or walks only with assistance and great effort.
17. Handwriting
 0 = normal
 1 =  some difﬁculty (e.g. slow, small letters); all words legible
 2 = considerable difﬁculty; not all words legible; may need to use block letters
 3 = majority of words are illegible.
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C. Motor Complications
18. Dyskinesias (presence)
0 =  absent 
1 =  present some of the time 
2 =  present a considerable part of the time
3 =  present most or all of the time.
19. Dyskinesias (severity)
 0 =  absent
 1 =  small amplitude
 2 =  moderate amplitude
 3 =  large amplitude 
20. Motor ﬂuctuations (presence of ‘off’ periods)
What proportion of the waking day is patient ‘off’ on average?
0 =  none
1 =  some of the time 
2 =  a considerable part of the time
3 =  most or all of the time.
21.  Motor ﬂuctuations (severity of ‘off’ periods)
 0 =  absent
 1 = mild end-of-dose ﬂuctuations
 2 =  moderate end-of-dose ﬂuctuations; unpredictable ﬂuctuations may occur
  occasionally
 3 =  severe end-of-dose ﬂuctuations; unpredictable on-off oscillations occur frequently.
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Abstract 
The objective of this study is to evaluate the responsiveness of items of the Activities 
of Daily Living (ADL) and Motor section of the Uniﬁed Parkinson’s Disease Rating Scale 
(UPDRS) in patients with Parkinson’s Disease (PD). A standardized Response Mean (SRM) 
per item was calculated using data of four trials (n = 376) that randomised patients with early 
PD to dopamine agonist (DA) monotherapy or placebo. In the ADL section the SRMs ranged 
from -0.04 (no effect) to -0.50 (moderate effect). Hand functions were the most responsive 
ADL items with “handwriting” showing the largest response. Self-assessed symptoms were 
the least responsive. In the Motor section, SRMs ranged from -0.09 to -0.60 with bradykinesia 
items showing the largest response, especially the item “ﬁnger taps”. The tremor items 
showed the smallest response, however rest tremor arms was much more responsive than rest 
tremor of the head and legs or postural tremor. SRMs in the placebo group ranged from 0.08 
to -0.21 in the ADL section and from -0.03 to -0.35 in the Motor section. ADL and Motor 
items have comparable and mostly small effect sizes. The most responsive items are in the 
ADL section hand functions and in the Motor section bradykinesia items. A more responsive 
ADL section would omit the self-assessed symptoms and the Motor section would retain only 
rest tremor arms of the tremor items.
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Parkinson’s Disease (PD) is a neurodegenerative disorder that can lead to major 
disability. Over the last decades, numerous treatments have been developed and reﬁned for 
patients with PD. As a consequence, measuring treatment effects has become a common 
practice in PD. The most commonly used measurement instrument for this purpose is the 
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS)1. The UPDRS is a multidimensional 
measure consisting four sections, of which the Activities of Daily Living (ADL) and Motor 
Examination are the sections mostly used. If the outcomes of these sections are to be useful 
as indicators of treatment success, the reliability, validity, and responsiveness (the accurate 
detection of change when it has occurred)2 of these sections need to be established. Previous 
research has documented the reliability and validity of these sections of the UPDRS but no 
study has addressed the responsiveness.3-8 The use of an instrument with sufﬁcient statistical 
power to detect differences between treatment groups over time can improve the clinical 
trial performance. In trials, treatment efﬁcacy is based on the change of the total score or 
subscales. However, individual items may differ in their ability to detect change, which may 
reﬂect response characteristics of particular disease features or methodological shortcomings 
of items that address the same features of the disease (e.g. bradykinesia or rigidity). Therefore, 
the aim of this study is to evaluate the responsiveness of items of the ADL and Motor section 
of the UPDRS. 
Methods
The responsiveness of an instrument can be determined by using data from a treatment 
with “known efﬁcacy”, when clinical changes are expected to occur. Therefore a literature 
search was conducted, using Medline and reference tracking, for trials that randomised early 
PD patients to dopamine agonists (DA) (pramipexole, pergolide or ropinerole) monotherapy 
or placebo. Studies were selected that had a similar study design with respect to study 
duration, patient selection and outcomes using the UPDRS part II (ADL) and part III (Motor 
Examination). Responsiveness of items was based on the change between baseline and 9 to 
12 weeks follow-up. The companies that were related to the identiﬁed studies were contacted 
and asked to provide study data. Data were obtained from four studies in early PD that 
compared placebo to DA monotherapy: pramipexole (max dose 4.5 mg/d), ropinerole (max 
RESPONSIVENESS OF IMPAIRMENTS AND DISABILITIES
58
dose 24.0 mg/d), ropinerole (max dose 10.0 mg/d) and pergolide (max dose 3.0 mg/d).9-12 
All patients with complete baseline and follow-up data were included. In total 376 patients 
(DA / placebo: 183/193) had data on change from baseline to follow-up, and were used for 
the analysis. 
Statistical methods 
Item responsiveness was calculated as a Standardized Response Mean (SRM): the 
mean change in score, divided by the standard deviation of the change in scores 13. The SRM 
is a frequently used measure of responsiveness that can be thought of as an indicator of the 
ability to distinguish ‘signal’ from ‘noise’. The SRM does not represent absolute change 
and therefore allows comparisons between different instruments. In this study a negative 
SRM indicates improvement whereas a positive SRM indicates deterioration. The studies 
were comparable with regard to the outcome measures, study duration, and patient sample 
characteristics but showed differences with respect to dose equivalence of the used dopamine 
agonists. However, in this study we were interested in the response proﬁle of the items of the 
ADL and Motor section to dopamine agonists as a medication group. Therefore an overall 
SRM was calculated for each item by weighting the SRM per study with the number of 
patients per study. SRMs were calculated separately for the DA and placebo group. Larger 
SRMs indicate greater responsiveness. To interpret the effect size we used Cohen’s criteria: ≥ 
0.2 = small; ≥ 0.5 = moderate; ≥ 0.8 = large effect.14 To compare the responsiveness of items 
that assess similar features, the ADL section was divided into the categories hand functions 
(4 items), midline functions (4 items) and self-assessed symptoms (5 items) (Table 1). The 
Motor section was divided into the categories bradykinesia (9 items), rigidity (5 items), 
tremor (7 items) and midline functions (6 items) (Table 2). Patients included in these studies 
were in the early stages of the disease and ﬂoor effects could be expected. Therefore, item 
baseline scores were examined for ﬂoor effects (present when 80% or more of the patients 
had a score = 0).15 
Results
ADL section
The mean (SD) total ADL score at baseline was 9.07 (4.56) with a mean (SD) item 
baseline score of 0.62 (0.39). At baseline, item means of the ADL section ranged from 0.12 
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(“falling”) to 1.34 (“tremor” and “handwriting”). Baseline ﬂoor effects were present for the 
items “swallowing”, “falling” and “freezing”. In the ADL section the SRMs ranged from 
-0.04 (“freezing”) to -0.50 (“handwriting”) (Table 1). The mean SRM of all ADL items was 
-0.30. Hand functions were the most responsive ADL items (mean SRM = -0.44), whereas 
midline functions (mean SRM = -0.29) and self-assessed symptoms (mean SRM = -0.20) 
showed no or small effects. Within the categories hand functions, midline functions, and 
self-assessed symptoms the most responsive functions were “handwriting”, “turning”, and 
“tremor”, respectively.
Table 1: Standardized Response Means (SRM) of the ADL section 
Category Item SRM-DA SRM-PL
Hand functions Handwriting -0,50 -0.04
Cutting -0,50 -0.21
Dressing -0,41 0.03
Hygiene -0,35 -0.02
Meana -0.44 -0.06
Midline functions Turning -0,41 -0.10
Walking -0,37 -0.05
Speech -0,19 -0.11
Swallowingb -0,19 0.05
Meana -0.29 -0.07
Self-assessed symptoms Tremor -0,47 -0.13
Fallingb -0,22 -0.03
Sensory symptoms -0,21 -0.07
Salivation -0,04 0.05
Freezingb -0,04 0.08
mean -0.20 -0.03
SRM-DA = Standardized Response Mean-Dopamine Agonist group 
SRM-PL= Standardized Response Mean-Placebo group
aindicates signiﬁcant difference (T-test; p<0.05) for means between  SRM-DA and SRM-PL 
bItems with ﬂoor effects; ≥ 0.2 = small; ≥ 0.5 = moderate; ≥ 0.8 = large effect
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Table 2: Standardized Response Means (SRM) of the Motor examination
Category Item SRM-DA SRM-PL
Bradykinesia Finger taps right -0,60 -0.28
Rapid alternating movements left -0,56 -0.08
Hand movement right -0,55 -0.21
Finger taps left -0,48 -0.13
Leg agility right -0,48 -0.23
Leg agility left -0,48 -0.09
Rapid alternating movements right -0,47 -0.19
Body bradykinesia -0,46 -0.29
Hand movements left -0,42 -0.14
Meana -0.50 -0.19
Rigidity Rigidity right leg -0,43 -0.13
Rigidity right arm -0,39 -0.27
Rigidity left leg -0,39 -0.13
Rigidity left arm -0,38 -0.24
Rigidity neck -0,27 -0.07
Mean -0.37 -0.17
Midline functions Facial expression -0,45 -0.35
Gait -0,38 -0.18
Posture -0,33 -0.14
Postural stability -0,30 -0.21
Speech -0,29 -0.16
Arising -0,25 -0.05
Mean -0.33 -0.22
Tremor Rest tremor right arm -0,47 -0.17
Rest tremor left arm -0,45 -0.05
Rest tremor right legb -0,23 -0.03
Rest tremor left legb -0,22 -0.05
Rest tremor headb -0,18 0.16
Postural tremor right -0,16 -0.06
Postural tremor left -0,09 -0.18
Meana -0.26 -0.05
SRM-DA = Standardized Response Mean- Dopamine Agonist group SRM-PL= Standardized Response Mean- 
Placebo group a indicates signiﬁcant difference (T-test; p<0.05) for means between SRM-DA and SRM-PL  
bItems with ﬂoor effects; ≥ 0.2 = small; ≥ 0.5 = moderate; ≥ 0.8 = large effect
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Motor section
 The mean (SD) total motor score at baseline was 22.81 (9.98), with a mean (SD) 
item baseline score of 0.75 (0.31). At baseline the most prominently involved items were 
“body bradykinesia” (1.27), “facial expression” (1.23) and “ﬁnger taps” (1.11). Baseline 
ﬂoor effects were present for three items: “rest tremor head” and “rest tremor of right and left 
leg”. In  the  Motor  section the SRMs ranged from -0.09  (“postural tremor left”)  to   -0.60
(“ﬁnger taps right”) (Table 2). The mean SRM of the items in the Motor section was -0.37. 
Three bradykinesia items showed a moderate effect, three tremor items showed no effect and 
all other items showed a small effect. Items related to bradykinesia were the most responsive 
items (mean SRM = -0.50), followed by rigidity (mean SRM = -0.37), midline functions 
(mean SRM = -0.33) and tremor (mean SRM = -0.26). Within the bradykinesia category 
“ﬁnger taps” was the most responsive item. Rigidity of the legs and arms was more responsive 
than rigidity of the head. Rest tremor of the arms showed a larger responsiveness than rest 
tremor of the head or legs or postural tremor. “Facial expression” was the most responsive 
item of the midline functions.
Placebo responsiveness
In the ADL section the SRMs of the items in the placebo group ranged from 0.08 
to –0.21 (Table 1). The item “cutting food” showed the largest placebo effect, which was 
still within the range of small effect sizes. No differences between the categories emerged 
in the placebo group. Contrary to the categories hand functions and midline functions, no 
signiﬁcant differences were found between the DA and placebo group for the category self-
assessed symptoms. 
In the Motor section the SRMs of items in the placebo group ranged from –0.03 to 
–0.35 (Table 2). The item “facial expression” had the highest placebo response. Items with 
a small effect size (SRM ≥ 0.2) were equally distributed among the categories bradykinesia, 
rigidity, and midline functions. The category tremor had the lowest mean SRM on placebo. 
Signiﬁcant differences emerged between DA and placebo for the categories bradykinesia and 
tremor, whereas a trend towards a signiﬁcant difference was found for the category rigidity. 
No difference between DA and placebo emerged for the category midline functions. 
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Discussion
In this study we evaluated the responsiveness of items of the ADL and Motor sections 
of the UPDRS to DA in patients with early PD. Responsiveness is important when a scale 
is employed to evaluate change over time. Several aspects may affect the responsiveness: 
timing of data collection, the patient group, and the type of treatment.16 Responsiveness might 
improve when the effect of a treatment is evaluated over a longer timeframe, but the progressive 
nature of PD likely would confound the evaluation of the true responsiveness of items. We 
therefore believe that a period of 12 weeks is an adequate choice. Floor effects impose limits 
on the degree of responsiveness of items even if items are potentially responsive. We found 
ﬂoor effects for the items “swallowing”, “freezing”, and “falling” in the ADL section. This 
is likely explained because our study focused on patients with early PD and these problems 
occur mostly in advanced stages of the disease.17;18 Floor effects were also found for rest 
tremor head and legs in the Motor section. These tremor items are rarely of importance in 
patients with PD. Overall, the effect sizes of the items in both the ADL and Motor section 
ranged from not demonstrable to moderate, but most effect sizes were small. The sensitivity 
to change of an item is a reﬂection of the treatment effect as well as the methodological 
quality of an item to detect change. Lacking a gold standard of change, it is often difﬁcult 
to disentangle both aspects. For this reason we categorized items that addressed a similar 
aspect of PD. Comparisons of SRMs between these categories may provide an indication of 
differential treatment effects. Comparisons of SRMs of similar items within a category may 
highlight methodological issues that explain differences of item responsiveness. Within the 
ADL section the category hand functions is the most responsive (small to moderate effect 
sizes), whereas the midline functions and self-assessed symptoms show no to small effects. 
Within the motor features of PD a distinction is often made between items that are more 
or less responsive to dopaminergic therapy.19 Bradykinesia and rigidity20 are considered to 
reﬂect dysfunction of dopaminergic pathways, whereas many midline functions21;22 including 
postural stability and swallowing reﬂect dysfunction of non-dopaminergic circuits. Tremor 
is considered intermediate in the dopaminergic-nondopaminergic spectrum.23;24 The data 
on responsiveness to dopaminergic medication in our study shows a gradual reduction of 
the mean SRM scores from the categories bradykinesia (-0.50), rigidity (-0.37), midline 
functions (-0.33) to tremor (-0.26). The category tremor is divided: items that assessed 
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rest tremor of the arms displayed the largest responsiveness (-0,45/-0,47) postural tremor 
shows no responsiveness and because of the ﬂoor effects, no conclusion can be drawn on 
the responsiveness of head and leg tremor. Furthermore, differences in responsiveness may 
also be related to the way data is obtained. Although physicians, patients and caregivers can 
assess the ADL section in a valid and reliable way25, the patient self-assessment could be 
more responsive.
The mean SRM of the items in the ADL and motor examination are comparable 
(-0.30 versus -0.37). Midline functions in the ADL and Motor section have comparable 
responsiveness as well as the item tremor in the ADL and the items rest tremor arms in the 
Motor section. In the ADL section the items “handwriting”, “tremor” and “turning” are the 
most responsive items of their categories. The largest variation in responsiveness is noted 
for items of the category self-assessed symptoms (-0.04 to -0.47). Within the bradykinesia 
category of the Motor section, the treatment effect is assumed equal and the higher SRM of 
the item “ﬁnger taps” indicates a better responsiveness of this item. Rigidity of the extremities 
was more responsive than rigidity of the head. In the Motor section the largest variation 
in responsiveness is noted for the category tremor (-0.09 to -0.47). “Facial expression” 
was the most responsive midline function item to both DA and placebo. Information on 
responsiveness to both a drug and placebo can be used in developing a more responsive 
instrument. However, it should be kept in mind that responsiveness of items may depend on 
the type of intervention.  Hence, studies on item responsiveness of different interventions 
in PD should be encouraged. The responsiveness to dopaminergic interventions of the ADL 
section could be improved by removing the self-assessed symptoms except for the item 
tremor that shows an almost moderate responsiveness. The responsiveness to dopaminergic 
interventions of the category tremor in the Motor section could be improved by removing the 
items assessing rest tremor of the head or legs and postural tremor. 
We investigated the responsiveness in both the DA and placebo group, and as 
expected, the SRMs were lower in the placebo group. In line with the ﬁndings of two studies 
by Goetz26;27 we found that within the motor section the placebo response was larger for 
bradykinesia and rigidity than for midline functions or tremor and the placebo response 
was larger in the motor than in the ADL section. Despite the possibility of expectation bias, 
the more subjective ADL section appears less susceptible to placebo effects than the more 
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objective motor examination. This knowledge on the placebo response should be considered 
when performing sample size and power calculations for clinical trials.  
It is important to realize that the responsiveness of the items does not necessarily 
reﬂect the importance of the change. A small change in “walking” could be more relevant to 
a patient than a larger change in “ﬁnger taps”. Anchor-based methods, in which the clinical 
outcomes are related to a patient-based external criterion of change, are required to calculate 
the minimum amount of change that indicates an important improvement (minimal clinical 
important difference, MCID). The MCID possibly differs between ADL and motor section. 
Responsiveness is an essential scale characteristic because the results of studies that evaluate 
change over time depend on the quality of the assessment scales. It is important to realize 
that not all subscales or items within the subscales similarly reﬂect change in the outcome 
measures. More non-responsive items in a scale can increase the measurement error and 
decrease the overall sensitivity to change of the instrument. Comparing the responsiveness 
of different instruments may help investigators to choose the best instruments, because a 
more responsive instrument can demonstrate a given treatment effect with a smaller sample 
size28. Furthermore, investigating the responsiveness of items within a scale can provide 
more insight in the underlying structure of the scale and may help with the improvement or 
development of new scales. A more responsive ADL section would omit the self-assessed 
symptoms and the Motor section would retain only rest tremor arms of the tremor items.
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Abstract
We developed a questionnaire to assess autonomic symptoms in patients with 
Parkinson’s disease (PD) and evaluated its reliability and validity. Based on the results of 
a postal survey in 46 PD patients, 21 multiple system atrophy patients, and 8 movement 
disorders specialists, items were included according to their frequency, burden and clinical 
relevance. The questionnaire was evaluated in 140 PD patients and 100 controls, and test-
retest reliability was established in a sample of 55 PD patients. The SCOPA-AUT consists of 
25 items assessing the following regions: gastrointestinal (7), urinary (6), cardiovascular (3), 
thermoregulatory (4), pupillomotor (1) and sexual (2 items for men and 2 items for women) 
dysfunction. Test-retest reliability was good. Autonomic problems increased signiﬁcantly 
with increasing disease severity for all autonomic regions, except sexual dysfunction. We 
conclude that SCOPA-AUT is a reliable and valid questionnaire that evaluates autonomic 
dysfunction in PD. 
 
CHAPTER 5
69
Parkinson’s disease (PD) has mainly been characterized in terms of motor 
impairments. Increasingly it has been recognized that the clinical spectrum of PD is more 
extensive, including also cognitive, mood, sleep and a broad spectrum of autonomic features 
involving gastrointestinal, urinary, sexual, cardiovascular, thermoregulatory, respiratory and 
pupillomotor functions.1-7 The overall prevalence of autonomic features varies considerably 
from 2% for urinary incontinence to 72% for constipation;8 and in part, they have been 
related with disease duration, disease severity or use of antiparkinsonian drugs.9;10 Autonomic 
dysfunction in PD patients is a serious problem, it is associated with depression and impacts 
on daily functioning and quality of life.11;12 For several autonomic symptoms, including 
gastrointestinal and urinary problems, orthostatic hypotension, and erectile dysfunction, 
therapeutic interventions have become available.13;14 
Despite a great deal of research, no reliable and valid instrument exists that 
encompasses the full spectrum of autonomic problems, thus the primary aim of this study was 
to develop a reliable and valid questionnaire for autonomic dysfunction in PD. Autonomic 
failure is also a frequent and prominent manifestation of multiple system atrophy (MSA).15 
Although the proﬁle of autonomic features is quite similar, autonomic dysfunction is more 
severe in MSA.16 Therefore the scale was designed to reﬂect autonomic features in MSA as 
well. The development of the SCOPA-AUT is part of a larger research project, the SCales 
for Outcomes in PArkinson’s disease (SCOPA), in which practical and clinimetric sound 
instruments for all relevant regions in PD are selected or developed. 
Methods
The ﬁrst phase consisted of the development of the questionnaire and, in the second 
phase we did a clinimetric evaluation of the SCOPA-AUT. The local medical ethics committee 
approved the study protocol.
Development of the SCOPA-AUT
Items were selected by an extensive review of the literature on autonomic symptoms 
in PD and MSA, and by consulting clinicians specializing in neurophysiology, gastro-
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enterology, gynaecology, urology, and sexology. Sleep disturbances are common in PD and 
may have various causes, including autonomic dysfunction. Due to the complexity of sleep, 
this aspect was not incorporated in the SCOPA-AUT, but a separate scale addressing sleep 
has been developed.17 
Each autonomic item was addressed by two questions: the frequency of the problem 
(“How often do you suffer from this problem?”) followed by a question addressing the burden 
to the patient (“How much does this problem bother you?”). All questions referred to the past 
month, except for syncope (past six months). The questionnaire was piloted in 16 patients for 
intelligibility of questions and response options, and unclear questions were rephrased.
This initial questionnaire was sent to 55 PD patients, selected from the outpatient 
movement disorders clinic of the Leiden University Medical Center who fulﬁlled the United 
Kingdom Parkinson’s Disease Society Brain Bank criteria (UKPDSBB) for idiopathic PD.18 
PD patients were selected to represent the different Hoehn and Yahr stages (H&Y).19 The 
questionnaire was also sent to 18 MSA patients of the same clinic who fulﬁlled the criteria 
for MSA,20 and to 20 MSA patients who attended a MSA meeting organized by the Dutch 
Parkinson’s Disease Society. Non-responders were reminded two weeks later. Ten movement 
disorder specialists were contacted to rate the clinical relevance of the items.
The mean, standard deviation (SD), and frequency distribution of each item was 
calculated for the frequency and the burden of the problem, as well as the product of frequency 
and burden. For either PD or MSA patients, items were selected with high frequency, high 
burden, a combination of high frequency and burden, or high clinical relevance as judged by 
the specialists. Redundant items (inter-item correlation above 0.80) were removed. 
  The selected items were rephrased into a single question evaluating the frequency 
of the problem, with four comprehensible response options ranging from 0 (“never”) to 3 
(“often”). The urinary and sexual regions have an additional response option, to indicate 
whether a subject used a catheter or had not been sexually active, respectively. The second 
questionnaire was again piloted for clearness and wording in 10 patients and ambiguous or 
misleading questions were rephrased.
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Evaluation of the SCOPA-AUT
A second postal survey was sent to 185 PD patients fulﬁlling the UKPDSBB 
criteria for idiopathic PD and 112 controls. To ensure sufﬁcient numbers of patients in all 
disease stages, 11 PD Patients in H&Y stages 4 and 5 participated in both studies. This 
strategy was not expected to bias the results, because all items had been rephrased and the 
time interval between the two questionnaires was more than seven months. Each patient was 
asked to provide two age-matched controls; partners were not allowed as control subjects. 
The postal survey also included demographic questions and a questionnaire on comorbid 
diseases (assessing 20 common chronic disorders).21 Information on disease severity, disease 
duration, and medication was obtained by chart review. Non-responders were reminded two 
weeks later. The ﬁrst 60 PD patients returning the questionnaire received a second mailing 
for the assessment of the test-retest reliability.
The median and frequency distribution of each item was calculated. Differences in 
items between the two groups were analyzed using the Mann-Whitney-U test. Items that did 
not discriminate between the PD and control group were removed from the questionnaire, 
provided this removal did not threaten the content validity. Test-retest reliability for items 
was assessed with a weighted kappa (K
w, 
quadratic weights). Means ± SD were calculated for 
the total and region scores, and differences between the two groups were analyzed using a 
Students t test for independent samples. Test-retest reliability for the total and region scores 
was analyzed using an intraclass correlation coefﬁcient (ICC). Known groups' validity was 
examined by comparing the SCOPA-AUT total and region scores between controls and 
patients and between controls and patients grouped by modiﬁed H&Y stages (mild, moderate, 
severe), using analysis of variance (ANOVA), post-hoc t-tests with Bonferoni correction, 
Kruskal-Wallis test, and ordinal regression. Spearman correlations were used to assess the 
correlation between the SCOPA-AUT total and region scores and disease duration, disease 
severity and dose of levodopa. 
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Results
Development of the SCOPA-AUT
A total of 45 items in the following regions were selected for the questionnaire: 
gastro-intestinal (13), urinary (8), cardiovascular (5), thermoregulatory (6), pupillomotor (1), 
skin (1), respiratory (2), and sexual (6 for men and 3 for women) dysfunction. An additional 
item assessed the use of medication in the aforementioned regions. Forty-six PD patients 
returned the questionnaire from the ﬁrst postal survey, a response rate of 84%. The mean ± 
SD age of the patients was 64.9 ± 9.2 years, and the disease duration 10.6 ± 5.9 years (Table 
1). Twenty-one MSA patients returned the questionnaire, a response rate of 53%. The mean ± 
SD age of the MSA patients was 63.9 ± 8.0 years, and the disease duration 6.8 ± 2.7 years. 
Table 1: Subject characteristics of in the ﬁrst and second postal survey (means ± SD)
Postal Survey 1 Postal Survey 2
Variable PD-1 MSA PD-2 Controls p
No. of  patients 46 21 140 100 -
Age (yr) 64.9 ± 9.2 63.9 ± 8.0 65.6 ± 10.9 61.4 ± 11.2 0.0051
Gender (m/f) 26/19 12/9 84/56 48/52 0.0662
Disease duration (yr) 10.6 ± 5.9 6.8 ± 2.7 9.9 ± 5.2
H & Y distribution:  1 
2 
3
4
5
3 
15 
15
10
1
4
53
48
25
3
1T-test and 2chi-square test of the subjects in the second postal survey
Of the 10 movement disorder specialists, 8 returned the questionnaire. Based on the 
results of the patients with PD and MSA, 23 and 24 items respectively fulﬁlled the criteria 
of frequency, burden, and product of both, resulting in a total of 25 items. The specialists 
indicated clinical importance for ten additional items. We aimed for a balanced representation 
of items on sexual dysfunction for both sexes. Therefore, the item “problem with orgasm”, 
that did not meet the criteria in the women's group, was retained for reasons of content. 
Eight items were removed because of redundancy. Overall, in the item selection process 17 
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items were removed (Table 2), and a total of 28 items remained in the following regions: 
gastrointestinal (10), urinary (6), cardiovascular (3), thermoregulatory (4), pupillomotor (1), 
and sexual (2 for men and 2 for women) dysfunction.
Table 2: Items deleted from the SCOPA-AUT
Items
Retrosternal pain
Persistent abdominal fullnes
Bloating
Straining to urinate
Hesitancy in starting urination
Postprandial hypotension
Avoidance of standing
Seborrhea
Hypohydrosis
Flushing
Nocturnal erections 
Erectile rigidity
Ability to maintain an erection
Absence of emission
Vaginal pain during sexual intercourse
Snoring
Sleep apnea
Evaluation of the SCOPA-AUT
In the second postal survey 143 of the 185 PD patients returned a questionnaire, a 
response rate of 77%. Three PD patients were excluded from the analyses because more than 
20% of their data was missing. The response rate for the test-retest assessment was 92%. 
Two PD patients were excluded from this analysis because more than 20% of their data was 
missing. The response rate in the control group was 93%. There were no differences between 
the characteristics of the total PD group and the sample used for the test-retest reliability. 
Compared to the PD patients, the subjects in the control group were signiﬁcantly younger and 
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included more women (Table 1). The analyses, therefore, were adjusted for age and sex. 
Table 3: Test-retest reliability in PD, median and presence of symptoms (% ≥1) in the PD 
and control group (second survey) 
Item PD Controls
K
w
1 Median % Median %
Swallowing/choking 0.69 1 61 0 20
Sialorrea 0.86 1 76 0 9
Dysphagia 0.74 0 40 0 11
Early abdominal fullnes 0.73 1 51 0 27
Gastric acid 0.90 0 32 0 29
Constipation 0.75 1 54 0 11
Straining for defacation 0.74 1 83 0 40
Faecal incontinence 0.56 0 14 0 3
Diarrhea 0.77 0 20 0 28
Flatulence 0.80 1 73 1 68
Urgency 0.79 1 68 0 21
Urinary incontinence 0.84 0 48 0 26
Incomplete emptying 0.69 1 55 0 28
Weak stream of urine 0.87 1 65 0 33
Frequency 0.45 1 90 1 77
Nocturia 0.76 2 91 2 89
Light-headed when standing up 0.75 1 51 0 15
Light-headed when standing for some time 0.69 0 38 0 10
Syncope 0.85 0 5 0 1
Hyperhidrosis during the day 0.73 1 52 0 31
Hyperhidrosis during the night 0.80 1 63 0 40
Cold intolerance 0.74 0 44 0 25
Heat intolerance 0.74 1 53 1 52
Over-sensitive to bright light 0.74 1 61 0 32
Men: erection problem 0.87 1 60 0 37
Men: ejaculation problem 0.73 1 57 0 43
Women: vaginal lubrication 0.77 0 48 1 52
Women: problem with orgasm 0.61 1 68 0 47
1K
w
= weighted kappa statistic
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Few data were missing, namely 0 to 1% per item in the control group and 0 to 4% 
in the PD group, except for the questions regarding sexual dysfunction, which had the most 
missing values, especially in female PD patients (11-13%). In total 46 to 50% of the women 
with PD and 39 to 40% of the women in the control group scored “not applicable” on these 
items, compared to 21 to 24% of the male PD patients and 10 to 17% of the men in the control 
group. Women who had missing values in the sexual dysfunction region or who scored “not 
applicable”, were signiﬁcantly older, both in the PD and in the control group.
Table 4: Mean (± SD) of the autonomic regions and the total score of the PD and control 
group, and test-retest reliability in the PD group.
Region PD Control p ICC¹
gastrointestinal dysfunction (7) 5.3 ± 3.1 1.4 ± 1.6 0.000² 0.90
urinary dysfunction (6) 7.1 ± 4.2 3.9 ± 2.4 0.000² 0.83
cardiovascular dysfunction  (3) 1.2 ± 1.3 0.3 ± 0.6 0.000² 0.83
thermoregulatory dysfunction  (4) 3.1 ± 2.4 1.8 ± 2.0 0.000² 0.82
pupillomotor dysfunction (1) 0.9 ± 0.9 0.4 ± 0.7 0.000³ 0.744
sexual dysfunction (2+2) 1.9 ± 1.8 1.3 ± 1.6 0.035² -
sexual dysfunction men (2) 2.0 ± 1.9 1.3 ± 1.7 0.055² 0.84
sexual dysfunction women (2) 1.7 ± 1.5 1.4 ± 1.5 0.440² 0.68
total autonomic score (23) 18.8 ± 8.5 8.8 ± 5.4 0.000² 0.87
¹intraclass correlation coefﬁcient; ²T-test; ³Mann-Whitney-U test; 4Weighted kappa statistic
Test-retest reliability for the individual items was high; K
w
 ranged from 0.45 to 
0.90 (Table 3). According to the criteria of Landis and Koch,22 two items had only moderate 
agreement (K
w
 between 0.41 and 0.60): “frequency” (0.45), and “faecal incontinence” (0.56). 
Compared to controls, PD patients had signiﬁcantly higher scores on all items (p < 0.05), 
except for the items “gastric acid”, “diarrhea”, “ﬂatulence”, and “syncope”. Similar results 
emerged when the analysis was corrected for age, or when analyzed separately for men and 
women. Compared to controls, PD patients had a signiﬁcantly higher use of medication for 
constipation (23% vs. 4%). The items “gastric acid”, “diarrhea” and “ﬂatulence” were removed 
because the remaining 7 items still covered the content of the region of gastrointestinal 
dysfunction adequately, whereas “syncope” was retained for reasons of content. The ﬁnal 
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version of the questionnaire included 25 items (Appendix), with the total score ranging from 
0 to 69, higher scores reﬂecting worse autonomic functioning. 
The ICC for the total score was 0.87 and the region scores ranged from 0.65 to 0.90 
(Table 4). PD patients had signiﬁcantly higher scores than control subjects on all regions 
except for items addressing sexual dysfunction in men and women (Table 4). Total and 
region scores showed signiﬁcant differences between groups based on H&Y stages, except 
for sexual dysfunction in women (Table 5). A signiﬁcant trend was present for these regions 
(again except for sexual dysfunction) with more autonomic problems in patients with more 
advanced PD. The Spearman correlation between the total score and H&Y stage was 0.60 
(p < 0.01), ranging from 0.20 to 0.70 for the regions. There were no signiﬁcant correlations 
between the total or region scores with disease duration or dose of levodopa. In the study 
participated 22 de novo PD patients, who scored signiﬁcantly higher than controls on the 
total and region scores. There were no differences in the scores between severely affected PD 
patients who participated in both the ﬁrst and second postal survey and those who participated 
in the second postal survey only. 
Table 5: Known-groups comparisons of total and region scores between controls and 
patients grouped by Hoehn & Yahr stage.
Region controls mild¹ moderate¹ severe¹ p Trend4
gastrointestinal dysfunction 1.4 4.4 5.7 6.9 0.000² +
urinary dysfunction 3.9 6.2 7.5 8.1 0.000² +
cardiovascular dysfunction 0.3 1.0 1.2 1.1 0.000² +
thermoregulatory dysfunction 1.8 3.1 3.1 3.9 0.000² +
pupillomotor dysfunction 0.4 0.8 0.9 0.8 0.000³ +
sexual dysfunction 1.3 1.6 2.3 1.5 0.055² -
sexual dysfunction men 1.3 1.6 2.6 1.5 0.062² -
sexual dysfunction women 1.4 1.4 1.8 1.6 0.890² -
total autonomic score 8.8 16.5 19.8 21.4 0.000² +
¹mild = H&Y1+2; moderate = H&Y3; severe = H&Y4+5, 
²ANOVA, ³Kruskal Wallis test,
4Trend: +/- indicates that a signiﬁcant trend is/is not present (p≤ 0.05), all models have good ﬁt
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PD patients recorded more comorbid diseases than subjects in the control group. 
However, some of these comorbidities may be results from autonomic dysfunction in PD: 
dizziness, urinary incontinence and bowel dysfunction. After the removal of these symptoms 
from the comorbidity questionnaire, no differences emerged between the groups.
Discussion
This study conﬁrms that autonomic dysfunction is a prominent aspect of PD, being 
present early in the disease and increasing with advancing H&Y stages. Although some 
studies have reported the use of a questionnaire to assess autonomic dysfunction, these 
questionnaires were never thoroughly validated.23 Selection of SCOPA-AUT items was 
based on patient response criteria for frequency and burden and clinical relevancy as judged 
by specialists. The response rates of the two postal surveys were high, which may indicate 
the importance of these aspects to patients. 
 As no gold standard or validated questionnaire for autonomic dysfunction in PD 
exists, our approach of developing the SCOPA-AUT was focused on the content and the 
clinical applicability of the questionnaire. The content validity of the SCOPA-AUT is good, 
based on opinions of experts and patients. One may question if items such as problems 
with swallowing, sialorrhea, and dysphagia reﬂect pure autonomic symptoms or motor 
impairments of PD, but we decided to include these items to cover the whole spectrum of 
problems within the alimentary tract.1 Some of the symptoms in the SCOPA-AUT could be 
side effects of medication instead of symptoms of the disease itself. However, we found no 
relation between the dose of levodopa and autonomic dysfunction, and even de novo patients 
indicated signiﬁcantly more autonomic dysfunction than controls.
The instrument shows good known-groups validity, as it adequately discriminates 
between PD patients and controls and between controls and PD groups of mild, moderate, 
and severe disease stages. The test-retest reliability is very high, both for the total and 
regions score and the individual items. In clinical management the neurologist could use the 
questionnaire (completed by the patient at home) to screen for autonomic regions that require 
more speciﬁc attention during the visit. Additionally, the scale could be used in trials to assess 
the changes in autonomic dysfunction.
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In agreement with other studies,24 the questions on sexual dysfunction had the most 
missing values, 13% in female PD patients (in addition to 50% answering “not applicable”). 
Only a small sample of women, thus, could be used for analysis, revealing no differences in 
sexual dysfunction between patients and controls. Women who did not answer these questions 
were signiﬁcantly older than responding women. Therefore, the results may be different in a 
younger sample.
To capture the spectrum of autonomic dysfunction in PD adequately, we aimed to 
include sufﬁcient numbers of PD patients of each H&Y stage. Eleven patients in H&Y stages 
4 and 5 were included in the second postal survey who had also participated in the ﬁrst postal 
survey. A potential bias of including these patients was considered small as the time interval 
between both surveys was at least seven months and all items had been rephrased. This 
ﬁnding was conﬁrmed by a post hoc analysis showing no differences in the scores of the two 
groups of severely affected PD patients. 
 PD patients had signiﬁcantly higher scores than controls, for the total score, most 
regions and most items. This is not in agreement with other studies, where only some of 
these symptoms were found to be signiﬁcantly different from those of controls.23;25 This 
discrepancy may be explained by the large size of our PD and control sample and  the 
broad range of PD patients regarding disease severity and duration. Within the PD group, 
patients with more advanced disease stages also had higher region scores, except for sexual 
dysfunction. This ﬁnding indicates that the questionnaire may have the ability to measure 
change, although responsiveness was not assessed in this study. Longitudinal studies of 
disease progression or the evaluation of effective treatment are needed to evaluate this 
property of the questionnaire. 
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Appendix - SCOPA-AUT
The response options are for all questions:  never, sometimes, regularly, often. In some regions extra 
response options are added. The questions concerning medication have the response options: no and 
yes.
1. In the past month have you had difﬁculty swallowing or have you choked?
2.  In the past month, has saliva dribbled out of your mouth? 
3. In the past month, has food ever become stuck in your throat?
4. In the past month, did you ever have the feeling during a meal that you were full very 
quickly?
5. Constipation is a blockage of the bowel, a condition in which someone has a bowel 
movement twice a week or less. In the past month, have you had problems with 
constipation? 
6. In the past month, did you have to strain hard to pass stools?
7. In the past month, have you had involuntary loss of stools?
8. In the past month, have you had difﬁculty retaining urine? (Extra: use catheter)
9. In the past month, have you had involuntary loss of urine?  (Extra: use catheter)
10. In the past month, have you had the feeling that after passing urine your bladder was not 
completely empty? (Extra: use catheter)
11. In the past month, has the stream of urine been weak? (Extra: use catheter)
12. In the past month, have you had to pass urine again within 2 hours of the previous time? 
(Extra: use catheter)
13. In the past month, have you had to pass urine at night? (Extra: use catheter)
14. In the past month, when standing up have you had the feeling of becoming either light-
headed, or no longer being able to see properly or no longer being able to think clearly? 
15. In the past month, did you become light-headed after standing for some time?
16. Have you fainted in the past 6 months?
17. In the past month, have you ever perspired excessively during the day? 
18. In the past month, have you ever perspired excessively during the night? 
19. In the past month, have your eyes ever been over-sensitive to bright light?
20. In the past month, how often have you had trouble tolerating cold?
21. In the past month, how often have you had trouble tolerating the heat? 
 
The following 3 questions are only for men: 
22. In the past month, have you been impotent (unable to have or maintain an erection)? (Extra: 
not applicable)
23. In the past month, how often have you been unable to ejaculate? 
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(Extra: not applicable)
23a. In the past month, have you taken medication for an erection disorder? (If so, which 
medicine?) (no; yes: _______)
The following 2 questions are only for women: 
24.  In the past month, was your vagina too dry during sexual activity? (Extra: not applicable)
25.  In the past month, have you had difﬁculty reaching an orgasm? (Extra: not applicable)
The following questions are for everyone:
26. In the past month, have you used medication for:
a. constipation? b. urinary problems?  c. blood pressure? d. other symptoms (no; yes: _____)
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Abstract 
Objectives: To evaluate the validity, reliability and potential responsiveness of the Beck 
Depression Inventory (BDI) in patients with Parkinson’s disease (PD).
Methods: Part 1: ninety-two patients with PD underwent a Structured Clinical Interview 
for DSM-major depression and based on this patients were considered depressed (PD-D) 
or non-depressed (PD-ND), subsequently patients ﬁlled in the BDI. Part 2: a postal survey 
consisting the BDI was performed in 185 PD patients and 112 controls. Test-retest reliability 
was assessed in 60 PD patients.
Results: The factor analysis revealed a cognitive-affective and a somatic factor. Cronbachs 
α for the BDI was 0.88. Mean BDI indicated signiﬁcant differences (p<0.001) between 
the PD and control group, between the PD-ND and PD-D group and between PD-ND and 
control group. In part 1, the ROC-curves showed that the AUC for the total BDI was 0.88. 
A cut-off was calculated for the BDI (14/15) that had the highest sum of sensitivity (0.71) 
and speciﬁcity (0.90). In part 2, the test-retest reliability for the BDI total score was 0.89 
(Intraclass Correlation Coefﬁcient). The smallest real difference (SRD) was 3.3 for the total 
BDI. 
Conclusions: The BDI is a valid, reliable and potential responsive instrument to assess the 
severity of depression in PD, however an adjusted cut-off is recommended. 
Keywords: Parkinson’s disease, depression, assessment, reliability, validity 
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Depression is common in Parkinson’s Disease (PD) (average prevalence 40%)1 with 
a large impact on the patient’s quality of life.2 Increasingly, depression is considered as one 
of the clinical domains of PD.3;4 Assessment of depression in PD has frequently relied on 
the use of generic depression rating scales, either semi-structured as the Hamilton rating 
scale for Depression (HAM-D)5 or self-assessed as the Beck Depression Inventory (BDI)6 
or the Hospital Anxiety and Depression Scale (HADS).7 The HAM-D has a good diagnostic 
performance but the interview is time-consuming. The HADS is a questionnaire that lacks 
somatic items, has satisfactory psychometric properties in PD,8 but cannot be applied to 
screen or diagnose depression.9 The BDI, like other depression scales, includes somatic 
items. This could decrease the psychometric properties of the BDI in PD as somatic items (of 
the HAM-D) were found to distinguish depressed and nondepressed PD patients worse than 
the nonsomatic items.10 A lower prevalence of depressed PD patients was found in another 
study,11 using only the nonsomatic items of the BDI, but no gold standard was used for 
comparison.
The BDI is one of the most frequently used self-rating scales for depression.12 
Despite its frequent use, the psychometric aspects of the BDI in PD have not been thoroughly 
evaluated. The internal consistency of the BDI is high in PD,13 and with two adjusted cut-off 
scores, either the sensitivity or the speciﬁcity of the BDI are sufﬁcient for either screening 
or diagnosing depression in PD.14 The objective of this study was to evaluate the validity, 
reliability and potential responsiveness of the BDI in the assessment of depression in patients 
with PD. The evaluation of the BDI is part of a larger research project, the SCales for Outcomes 
in PArkinson’s disease (SCOPA), in which feasible and clinimetric sound instruments for all 
relevant domains in PD are selected or developed.
  
Methods
Participants 
PD patients fulﬁlled the United Kingdom Parkinson’s Disease Society Brain 
Bank criteria for idiopathic PD (UKPDSBB),15 and were able to read and understand 
Dutch. Subjects without diseases of the central nervous system, who were able to read 
and understand Dutch, were eligible as controls. Partners were not allowed as controls 
because having a partner with PD may inﬂuence their outcomes.             
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The local medical ethics committee approved the study protocol.
Design
This study was carried out in two parts. Part 1: Consecutively referred PD patients 
of the movement disorders clinic of the Maastricht University Hospital underwent a 
protocolized examination using the depression module of the Structured Clinical Interview 
for DSM-depression (SCID-D),16 to verify major depressive disorder and classifying patients 
into major depressed (PD-D) or nondepressed (PD-ND). In addition, all patients were asked 
to complete the BDI. The presence of dementia was determined based on the DSM-IV criteria. 
This study was an extension of a previous study14 (including 53 patients) in order to increase 
power for additional analyses. 
Part 2: A postal survey including the BDI was performed in 185 PD patients who 
visited the outpatient movement disorders clinic of the Leiden University Medical Center. 
Disease speciﬁc information was obtained from patient records: Hoehn and Yahr staging 
(H&Y)17 for disease severity, disease duration, and medication. Non-responders were 
reminded by telephone after two weeks. Test-retest reliability was assessed in 60 PD patients, 
who received a second mailing two weeks after returning the ﬁrst questionnaire. Patients 
provided control subjects of approximately the same age (age difference less than 10 years). 
Statistical analysis
Data were entered and analyzed using SPSS for windows 11.0. Subjects with more 
than 20% of the data missing were excluded from the analysis. Analyses were done with PD 
patients from part 1 and 2 separately or combined (total PD group). Total PD group. Items 
were evaluated for ﬂoor and ceiling effects (≥ 80% response option 0 or 3), and item-total 
correlations (≥ 0.20).18 A principal component factor analysis was performed to explore the 
factor structure of the BDI. Differences in items and means between the groups were analyzed 
using the Mann-Whitney-U test. and Student’s T-test for independent samples, respectively. 
The internal consistency was assessed using Cronbach’s α. 
PD part 1. The discriminative properties of the BDI were assessed by way of Receiver 
Operating Characteristic curves (ROC curves), which display the sensitivity and speciﬁcity 
to diagnose depression for different cut-offs. PD  part 2. Test-retest reliability for items was 
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assessed with a weighted kappa (K
w, 
quadratic weights) whereas the test-retest reliability for 
the total BDI score was assessed using an Intraclass Correlation Coefﬁcient (ICC). As an 
indicator of potential responsiveness, the smallest real difference (SRD) was calculated using 
the following formula: SRD = 1.96 x √2 x SEM.19 (SEM is standard error of measurement: 
√total variance x √(1-ICC)). 
Results
Participants
Ninety-two PD patients participated in part 1: 21 (19%) PD patients were major 
depressed and 71 were not depressed. Major depressed and non-depressed patients did not 
differ signiﬁcantly with respect to age, disease duration, sex, or H&Y stage. One hundred 
and thirty-two PD patients (71%) responded to the mail survey. In the control group, 104 of 
the 112 subjects (93%) returned the BDI. Five patients and three control subjects had more 
than 20% missing values and their data was removed. The response rate for the test-retest 
assessment was 92%. The PD patients in part 1 and 2 did not differ signiﬁcantly with respect 
to age but PD part 1 had a signiﬁcant longer disease duration (Table 1). The control group 
was signiﬁcantly younger than both PD groups, and included signiﬁcantly more men than the 
PD part 2 group. Therefore, analyses with the control group were corrected for age and sex.
Table 1: Characteristics of participants in both parts of the study
Part 1 Part 2  
PD
1
C PD
2
N 92 101 127
Age (yrs) 67.3 (10.7) 60.8 (11.7) 65.0 (10.9)
Sex (% male) 48/44 (52%) 49/52 (49%) 79/48 (62%)
Disease duration (yrs) 5.8 (5.0) - 9.3 (4.9)
Hoehn &Yahr stage 11/63/15/1/0 - 3/54/53/15/2
C: Controls; PD
1+2
: Parkinson’s Disease patients of part 1+2 
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Analyses in the total PD group
Five items had ﬂoor effects but none of the items showed ceiling effects. In the 
control group 14 items had ﬂoor effects. All item-total correlations exceeded 0.20 (range 
0.26-0.71). The total PD group scored signiﬁcantly higher than controls on 16 of the 21 items 
(Table 2).
Table 2: BDI items: median (interquartile range), test-retest reliability and factor loadings 
item PD C kappa factor 11 factor 21
Mood* 0 (0,0) 0 (0,0) 0.69 0.63
Pessimism* 0 (0,1) 0 (0,0) 0.58 0.49 0.28
Sense of failure* 0 (0,0) 0 (0,0) 0.38 0.83
Lack of satisfaction* 1 (0,1) 0 (0,1) 0.45 0.50 0.30
Guilty feeling 0 (0,0) 0 (0,0) 0.31 0.87
Sense of punishment 0 (0,0) 0 (0,0) 0.72 0.74
Self-hate* 0 (0,0) 0 (0,0) 0.59 0.86
Self accusations 0 (0,0) 0 (0,0) 0.44 0.58
Suicidal ideas 0 (0,0) 0 (0,0) 0.89 0.26
Crying spells* 0 (0,1) 0 (0,0) 0.42 0.35
Irritability* 0 (0,1) 0 (0,1) 0.72 0.28
Social withdrawal* 0 (0,1) 0 (0,0) 0.41 0.40 0.37
Indecisiveness* 1 (0,2) 0 (0,0) 0.66 0.53
Body image* 0 (0,0) 0 (0,0) 0.64 0.49
Work inhibition* 1 (1,2) 0 (0,1) 0.69 0.60
Sleep disturbance* 1 (0,2) 0 (0,1) 0.86 0.35
Fatigability* 1 (1,2) 1 (0,1) 0.78 0.53
Loss of appetite* 0 (0,1) 0 (0,0) 0.75 0.61
Weight loss* 0 (0,1) 0 (0,0) 0.81 0.54
Somatic preoccupation* 1 (0,1) 0 (0,0) 0.63 0.58
Loss of libido 1 (0,1) 0 (0,1) 0.81 0.59
BDI=Beck Depression Inventory; PD=Parkinson’s Disease (part 1+2); C= Control group; 1extraction method: 
principal component analysis; rotation method: oblique with Kaiser normalization; only factor loadings > 0.25 are 
presented, the highest factor loadings are in boldface; *Mann Withney U test (p<0.05)
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Factorial validity: Inspection of the scree plot indicated that a two or three factor 
structure was appropriate explaining 40% and 45% of the variance, respectively. The content 
of the three-factor structure was difﬁcult to interpret, especially the 5 items of the third factor 
were difﬁcult to name. The two-factor structure was clearer: factor 1 included cognitive-
affective items, and factor 2 included somatic items, together with the item “indecisiveness” 
(Table 2). Only the item “social withdrawal” clearly double loaded. Based on this two-factor 
solution a cognitive-affective (11 items) and a somatic (10 items) subscore were calculated. 
Internal consistency: Cronbach’s α for the total BDI was 0.88, for the cognitive-affective 
factor 0.85 and for the somatic factor 0.74. 
Analyses in part 1
Five patients in de PD-ND (7.0%) and 2 patients in de PD-D group (9.5%) fulﬁlled 
the DSM-criteria for dementia. The PD-ND demented patients did not differ signiﬁcantly on 
the BDI from the non-demented PD-ND patients (p=0.191).
Criterion validity: Signiﬁcantly higher item scores were obtained for the PD-D group 
compared to the PD-ND group, except for the somatic items “body image” and “sleep 
disturbance”. The PD-ND patients scored signiﬁcantly higher than control subjects on ten 
items (7 somatic and 3 cognitive-affective items). Mean BDI total and subscores indicated 
signiﬁcant differences between the total PD and control group, between the PD-ND and PD-
D group and between the PD-ND and control group (Table 3).
Table 3: BDI total and subscores
Part 1 Part 2 Part 1 + 2
PD-ND PD-D C PD
N 71 21 101 219
BDI1,2,3 8.6 (5.0) 19.7 (9.1) 5.0 (4.0) 11.8 (8.2)
somatic1,2,3 6.3 (3.4) 11.3 (4.9) 3.6 (2.7) 7.9 (4.7)
cognitive-affective1,2,3 2.4 (2.2) 8.5 (6.2) 1.4 (2.1) 3.9 (4.5)
BDI=Beck Depression Inventory; C=Controls; PD= Parkinson Disease; 
PD-ND= nondepressed PD; PD-D= depressed PD; 
T-test signiﬁcant differences (p<0.000) between 1C and PD, 2C and PD-ND, and 3PD-ND and PD-D
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Discriminant validity: ROC-curves showed that the Area Under the Curve (AUC) 
for the total BDI was 0.88, for the somatic 0.79, and for the cognitive-affective subscore 
0.86. The optimal cut-off that had the highest sum of sensitivity (0.71) and speciﬁcity (0.90) 
was 14/15; this means that a score of 14 or less indicates no depression whereas 15 or more 
indicates depression. Sensitivity and speciﬁcity for the optimal cut-offs of the cognitive-
affective (4/5) and the somatic (6/7) subscale were 0.71/0.87 and 0.86/0.54, respectively. 
Analyses in part 2
Reliability: The test-retest reliability for the individual items ranged from 0.31-0.86 
(K
w
) (Table 2). Two items had only a fair agreement (K
w
< 0.40). ICCs for the BDI total 
score and the somatic subscale were both 0.89, and for the cognitive-affective subscale 0.90. 
Potential responsiveness: The SRD for the total BDI was 3.3; this is 5% of the maximum 
BDI score. The SRD for the somatic subscale was 2.8 (9% of the maximum), and for the 
cognitive-affective subscale 1.8 (5% of the maximum).
Discussion
The BDI is a self-completed instrument for depression that was found to have good 
test-retest reliability and internal consistency in PD patients. Test-retest reliability of only 
two items was low. This variability may be related to ﬂuctuations, but it was not assessed 
whether patients were on or off when completing the BDI. Five items in the PD group had 
ﬂoor effects. Floor effects hamper the differentiation between groups: of ﬁve items that did 
not differentiate between PD and controls, three items had ﬂoor effects. Although these items 
might not address prevalent features, they were able to differentiate between PD-D and PD-
ND. The factor analysis suggested a cognitive-affective and a somatic factor, both with high 
internal consistency. Earlier research in university students20 and depressive in-patients21 
reported similar factor solutions and a not very high explained variance of approximately 
40%. The item “indecisiveness” loaded in our study on the somatic factor, whereas in other 
studies this item was cognitive-affective.13;20 Also the items “body image” and “crying spells” 
loaded on the somatic factor, but these could very well be addressed to having PD.
Compared to controls, PD-ND had signiﬁcantly higher BDI scores. This suggests 
that PD-ND patients have mood disturbances without fulﬁlling the DSM-IV criteria of major 
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depression. A limitation of this study is that patients with minor depression were allocated in 
the PD-ND group. On the other hand, this difference underscores the shared content of the 
BDI and PD, especially because controls and PD-ND differ signiﬁcantly on seven somatic 
items and only three cognitive-affective items. 
Although dementia and depression may have overlapping symptoms, the percentage 
of demented patients in both groups was similar. Furthermore, the demented patients in 
the PD-ND group did not score signiﬁcantly higher then the rest of that group. In a PD 
population the BDI should be used but with an adjusted cut-off score, of 14/15. However, 
there is no ideal cut-off with both high sensitivity and speciﬁcity. The previous cut-off found 
by Leentjens,14 differs slightly from the cut-off proposed in this study, which is based on a 
more extended population. 
Major depressed PD patients score higher than nondepressed PD patients on the 
BDI and on eight of ten somatic items, which cannot be explained by disease duration or 
severity. We conclude therefore that the somatic items “body image” and “sleep disturbance” 
assess disease characteristics and not depression. Although the HADS lacks somatic items, 
the internal consistency and test-retest reliability of the HADS8 and the BDI are very similar. 
The HADS showed no ﬂoor or ceiling effects in PD but the BDI items are more in accordance 
to the DSM criteria for depression.16 The use of the DSM criteria may also be questionable 
as a gold standard for depression in PD as these also include somatic items. However, for the 
diagnosis of depression at least one of the symptoms must either be depressed mood or loss 
of interest or pleasure. Furthermore, no better criterion is currently available.
The SRD of the total BDI in PD is 3.3, implying that in follow-up studies, a difference 
of more than 3.3 on the BDI is indicative of a real change. A low SRD indicates high potential 
responsiveness because smaller changes are required to exceed measurement error. Although 
the BDI has the potential to be a responsive instrument, this needs to be further explored for 
interventions of known efﬁcacy. 
In conclusion the BDI is a reliable, valid and potential responsive instrument to 
assess the severity depression in PD. Although the somatic items increase the BDI score 
in PD, they do not decrease the internal consistency or the ability to differentiate between 
depressed and nondepressed PD patients. Therefore, we recommend that the BDI be used 
with an adjusted cut-off. 
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Abstract
Study objectives: To develop a short and practical scale (SCOPA-SLEEP) that evaluates 
nighttime sleep and daytime sleepiness. The scale is developed for research in Parkinson 
disease but may be of value for other somatic diseases.
Design: Postal survey including four instruments, the SCOPA-SLEEP nighttime sleep (5 
items) and daytime sleepiness (6 items), the Pittsburgh Sleep Quality Index and the Epworth 
Sleepiness Scale. 
Setting: Movement Disorders Center, Department of Neurology, Leiden University Medical 
Center, Leiden, The Netherlands.
Participants: 143 patients with Parkinson disease and 104 controls.
Interventions: N/A.
Measurements and Results: Reliability of the scale was high: internal consistency of the 
nighttime sleep and daytime sleepiness scales were 0.88 and 0.91, respectively (Cronbach 
alpha), and test-retest reliabilities were 0.94 and 0.89, respectively (intraclass correlation 
coefﬁcient). Scale scores differed signiﬁcantly between patients and controls (p < 0.001). 
Construct validity was assessed by correlations with scales that addressed similar constructs. 
Correlation between the nighttime sleep scale and the Pittsburgh Sleep Quality Index was 
0.83 (p < 0.001), and the correlation between the daytime sleepiness scale and the Epworth 
Sleepiness Scale was 0.81 (p < 0.001). Factor analysis revealed one factor each for both 
scales, indicating that the scales measure one construct, which justiﬁes the calculation of 
sumscores. The coefﬁcient of variation of both the nighttime sleep and daytime sleepiness 
scale was higher than that of the Pittsburgh Sleep Quality Index and the Epworth Sleepiness 
Scale, indicating a better ability to detect differences between individuals. 
Conclusions: The SCOPA-SLEEP is a reliable and valid instrument for assessing nighttime 
sleep and daytime sleepiness in patients with Parkinson disease. 
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Insomnia and hypersomnia occur frequently in the general population and increase 
with higher age. Several studies found even higher prevalences of both types of sleep 
problems in patients with Parkinson’s disease (PD).1-3 Poor nighttime sleep is associated 
with lower quality of life of patients and their spouses,4-6 while excessive daytime sleepiness 
may be bothersome or even dangerous. A few studies have reported the occurrence of ‘sleep 
attacks’ among patients with PD, potentially causing hazardous situations.7-9 Sleep problems 
in PD, therefore, merit particular attention and in order to assess this issue in a longitudinal 
study, we were interested in a concise, practical and clinimetric sound instrument that could 
be used to assess nighttime sleep (NS) problems and daytime sleepiness (DS) in patients 
with this condition. The questionnaire should be appropriate for both research and clinical 
practice. However, none of the existing sleep scales matched these objectives. Some scales 
lacked conceptual clarity and combined scores on items addressing different constructs into 
a total score (eg, Pittsburgh Sleep Quality Index (PSQI),10 Parkinson’s Disease Sleep Scale11). 
Other scales had potential problems with face validity and were either too short (Stanford 
Sleepiness Scale,12 Karolinska Sleepiness Scale13), lacked relevant items (Sleep Problems 
Scale14), or asked patient to indicate the chance of falling asleep in situations they possibly did 
not experience (Epworth Sleepiness Scale15). Still other scales were not suitable for clinical 
use, because they were too long, the calculation of sumscores was complex (Pittsburgh Sleep 
Quality Index), or combined continuous and categoric responses (St. Mary’s Hospital Sleep 
Questionnaire16). Additionally a number of scales were not appropriate because they involved 
diagnostic instruments (Sleep Disorders Questionnaire17) or were intended for particular 
patient groups (eg, narcolepsy) or particular interventions (e.g., pharmacological in the Leeds 
Sleep Evaluation Questionnaire18).
We, therefore, decided to develop and validate a new scale, the SCOPA-SLEEP, that 
evaluates both NS and DS. We were especially interested in the performance of this scale in 
PD in view of future studies, and therefore patients with this condition were involved in the 
development process. The development of this scale is part of a larger research project on 
SCales for Outcomes in PArkinson’s disease (SCOPA).19
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Methods
Scale development
Items in the NS scale were selected from the literature and evaluated whether patients 
experienced problems with respect to their nocturnal sleep. It was hypothesized that together 
these items would reﬂect a subject’s perceived sleep quality. The items were judged by experts 
and piloted among patients with PD regarding comprehensibility and clarity. Testing was 
continued until no further problems were encountered and patients understood all items well. 
The DS scale was developed similarly and evaluated how often patients had fallen asleep in 
daytime, a subject had experienced difﬁculty staying awake, and whether falling asleep in 
daytime was considered a problem. The SCOPA-SLEEP thus consists of two parts. The NS 
subscale addresses NS sleep problems in the past month and includes ﬁve items with four 
response options. Subjects have to indicate how much they were bothered by particular sleep 
problems, ranging from 0 (not at all) to 3 (a lot). The ﬁve items address sleep initiation, sleep 
fragmentation, sleep efﬁciency, sleep duration, and early wakening. The maximum score of 
this scale is 15, with higher scores reﬂecting more severe sleep problems. One additional 
question evaluates overall sleep quality on a 7-point scale (ranging from ‘slept very well’ to 
‘slept very badly’). The score on this item is not included in the score of the NS scale, but 
is used separately as a global measure of sleep quality. The DS subscale evaluates daytime 
sleepiness in the past month and includes six items with four response options, ranging from 
0 (never) to 3 (often). Subjects indicate how often they fell asleep unexpectedly, fell asleep in 
particular situations (while sitting peacefully, while watching TV or reading, or while talking 
to someone), how often they had difﬁculty staying awake, and whether falling asleep in the 
daytime was considered a problem. The maximum score is 18, with higher scores reﬂecting 
more severe sleepiness. 
Participants
Since patients with PD reported more sleep problems than controls in almost all 
previous studies, the scales would have to be able to detect these differences, and subjects 
without PD were therefore included as a control group. 
Patients. Patients who visited the outpatient clinic of the Department of Neurology of 
the Leiden University Medical Center and fulﬁlled the United Kingdom Parkinson’s Disease 
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Society Brain Bank criteria for idiopathic PD,20 were included. Patients were excluded if they 
also had other diseases of the central nervous system or were not able to read or understand 
Dutch. 
Controls. Subjects without PD who were able to read or understand Dutch were 
eligible as controls, provided that they had no history of diseases of the central nervous 
system. 
Recruitment. Questionnaires were sent to eligible patients. An introductory letter 
provided information on the goal of the study and asked patients to provide the names of two 
persons, one man and one woman, who would consent to participate as control subjects. The 
age difference between the patient and his or her controls was not to exceed 10 years. The 
introductory letter emphasized that only the names of persons who explicitly expressed their 
willingness to participate were to be provided. Partners were not eligible as controls, since 
nocturnal sleep problems of patients could affect the partner’s sleep pattern.6;21 Relatives of 
patients were not excluded. Response was interpreted as consent to participate. The study 
was approved by the medical ethics committee of the Leiden University Medical Center.
Scale evaluation
A postal survey was sent to potential participants. The included questionnaires were 
the SCOPA-SLEEP (appendix), the PSQI,10 and the ESS.15 Eight additional questions were 
used to evaluate use of sleep medication, sleep initiation time (minutes), time awake per 
night (hours), actual duration of NS (hours), duration of daytime sleep (minutes), and how 
often subjects had ‘planned naps’, ‘unplanned naps’, or ‘fallen asleep quite unexpectedly’ 
in the past month. Response options for the latter three questions ranged from ‘not at all’ to 
‘every day’. The PSQI, ESS, and the eight additional questions were included to assess the 
construct validity of the SCOPA-SLEEP. The PSQI and the ESS were included because they 
are frequently used and have previously been used in studies involving patients with PD. 
The PSQI evaluates several aspects of NS and consists of 19 self-rated questions and ﬁve 
questions rated by the bedpartner or roommate.10 The latter ﬁve questions are used for clinical 
information only and are not tabulated in the scoring of the PSQI. Scores are ﬁrst grouped in 
seven domains and next recoded to a 0 to 3 scale. The seven domains include subjective sleep 
quality, sleep latency, sleep duration, habitual sleep efﬁciency, sleep disturbances, use of 
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sleep medication, and daytime dysfunction. Both the total score and the subscale scores can 
be used. The total score has a maximum of 21, with higher scores reﬂecting greater problems. 
The developers advise a cut-off score of 5/6 to separate good from bad sleepers.10
The ESS evaluates DS. In this scale, the individual is asked to rate the chance of 
dozing off for eight different situations.15 There are four response options, ranging from 0 
(would never doze) to 3 (high chance of dozing). The maximum score is 24, with higher 
scores reﬂecting more severe sleepiness. Healthy controls usually have scores of 10 or less. 
Scores greater than 10 are considered indicative for excessive sleepiness.22 Scores of 16 or 
greater indicate a high level of DS, but are by themselves not diagnostic of a particular sleep 
disorder.15 
Participants were asked to complete the questionnaires within one week. After two 
weeks, non-responders were contacted by telephone and the investigator inquired whether 
the subject still considered participating. Patients who returned their questionnaires within 
one week were asked to complete the SCOPA-SLEEP a second time two weeks later, for the 
evaluation of the test-retest reliability. Information from the questionnaires of participating 
patients was combined with information from patient records (ie, disease severity, disease 
duration, and medication use) to assess ‘known-groups’ validity. Disease severity was 
evaluated at each control visit and assessed by the Hoehn and Yahr (H&Y) staging system.23 
An H&Y 1 is the mildest stage with only unilateral symptoms, whereas H&Y 5 is the 
most severe stage in which patients are wheelchair-bound or bedridden. Comorbidity was 
assessed by means of a standard questionnaire, evaluating the 22 most common diseases. 
This questionnaire includes an extra question in which respondents are asked to indicate the 
presence of other diseases.
Statistical analysis
Data were entered and analyzed with SPSS for Windows 10.0 (SPSS Inc, Chicago, 
Ill). Questionnaires were excluded if they had more than 20 % of values missing. 
Data quality and score distribution. The quality of the data was considered acceptable 
if item scores were missing in less than 10 % of the patients24 and item-total correlations in 
the patient group exceeded 0.20.25
Reliability. Internal consistency of the scales was assessed with Cronbach α. Test-
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retest reliability for individual items was assessed with a weighted kappa (K
w
; quadratic 
weights), whereas an intraclass correlation coefﬁcient (ICC) was used for the total score. 
Validity. Age, disease severity, and male-female ratio of responders were compared 
with those of non-responders, using t-tests, Mann-Whitney-U tests, and Chi-square tests, 
respectively. Independent samples t-tests were used to compare scores of patients and 
controls, and scores of patients that were on medication (levodopa, dopamine-receptor 
agonists, or sleep medication) versus those who were not. The signiﬁcance threshold was set 
at 0.05. Construct validity of the SCOPA-SLEEP was assessed by calculating the correlation 
between this scales and scales that addressed similar constructs, using Pearson’s correlation 
coefﬁcient (r). This coefﬁcient was also used to explore the relation with disease duration. 
Spearman’s correlation coefﬁcient (r
s
) was used if the correlation involved subscales of the 
PSQI and the ‘global sleep quality’ item. Known-groups validity was assessed by comparing 
the NS and DS scores of patients with different disease severity, using analysis of variance 
(ANOVA). To discriminate groups of patients with different disease severity, patients were 
classiﬁed as mild (H&Y 1 and 2), moderate (H&Y 3), or severe (H&Y 4 and 5). Stages 1 
and 2 on the one hand, and 4 and 5 on the other hand, were collapsed because patients in 
H&Y stages 1 and 5 were underrepresented, a common ﬁnding in studies involving patients 
with PD. A principal component factor analysis with orthogonal rotation was performed to 
explore the underlying structure of the scales. Coefﬁcients of variation (CV) were calculated 
to assess the discriminative properties of the scale. The CV is calculated by dividing the SD 
of the score by the mean of the score. Higher values for CV indicate a better ability to detect 
differences between individuals.
Results
Response rate and sample characteristics
A postal survey was sent to 185 patients with PD and 112 controls; 143 patients 
returned their questionnaires. One questionnaire had more than 20 % of the data missing 
and was excluded. Thus 142 usable questionnaires remained, constituting a response rate of 
76.7%. Of the controls, 104 returned their questionnaires; four questionnaires were excluded 
because the age difference with the corresponding patient was more than 10 years. Therefore, 
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100 usable questionnaires (89.3 %) from controls were available for analysis. Of the 60 
patients who returned their questionnaire within one week, 56 completed the SCOPA-SLEEP 
a second time. One questionnaire was subsequently removed from the analysis because too 
much data was missing, leaving a response rate of 91.7 % (table 1).
Table 1: Characteristics of participants
Patients Controls p
n 142 100
% male 60.5 48.0 0.0531
mean (SD) age (years) 65.6 (10.8) 61.4 (11.2) 0.0042
H&Y 1 4 (2.8 %)
H&Y 2 57 (40.1 %)
H&Y 3 52 (36.6 %)
H&Y 4 26 (18.3 %)
H&Y 5 3 (2.1 %)
mean (SD) disease duration (years) 9.9 (5.4)
n on levodopa 73 (51 %)
mean (SD) levodopa dose in users (mg) 665 (361)
n on dopamine agonists 60 (42 %)
n on levodopa + dopamine agonists 54 (38 %)
n on sleep medication 27 (19%) 7 (7%) < 0.0011
1Chi-square test; 2t-test
Differences between responders and non-responders in the patient group were 
not signiﬁcant for disease severity and age, but the proportion of women among the non-
responders was signiﬁcantly higher (p < 0.05). The mean disease duration of the patients was 
9.9 (SD 5.4) years. Disease severity was mild in 61 patients (43.0 %), moderate in 52 patients 
(36.6 %), and severe in 29 patients (20.4 %). The male-female ratio did not differ signiﬁcantly 
between patients and controls (p = 0.053), but controls were signiﬁcantly younger (table 1). 
None of the controls reported a sleep disorder in the comorbidity questionnaire. 
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Table 2: Reliability of sleep scales in patient group
Cronbach α item-total1 ICC sum2 K
w
 items3
SCOPA-NS (night-time sleep) 0.88 0.48-0.85 0.94 0.82-0.94
 1: difﬁculty falling asleep 0.48 0.90
 2: been awake too often 0.77 0.82
 3: lying awake too long 0.85 0.86
 4: waking too early 0.72 0.83
 5: had too little sleep 0.77 0.90
Overall sleep quality N/A N/A N/A 0.91
Pittsburgh Sleep Quality Iindex 0.77 0.27-0.71 * *
SCOPA-DS (daytime sleepiness) 0.91 0.55-0.88 0.89 0.49-0.82
 1: falling asleep unexpectedly 0.88 0.79
 2: falling asleep while sitting 0.86 0.78
 3: falling asleep while watching TV 0.82 0.81
 4: falling asleep while talking 0.55 0.78
 5: difﬁculty staying awake 0.76 0.82
 6: falling asleep considered a problem 0.64 0.49
Epworth Sleepiness Scale 0.86 0.56-0.71 * *
1corrected item-total correlations; 2intraclass correlation coefﬁcient for the sumscore, calculated over 2 week 
interval; 3weighted kappa of items, calculated over 2 week interval; *reproducibility not assessed for this scale; 
N/A: not applicable
Scale evaluation
Data quality and score distribution.The quality of the data was good. None of the 
items had missing values in more than 10 % of the patients, indicating good acceptability. 
All item-total correlations exceeded 0.20. Patients used the full score range in both scales. 
Twenty-ﬁve patients (17.7 %) had a score of 0 in the NS scale, whereas 2 patients (1.4 %) 
scored 15. Seventeen patients (12.1 %) had a score of 0 in the DS scale, whereas one patient 
(0.7 %) scored 18. 
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Reliability. Cronbach α for the NS subscale was 0.88, with corrected item-scale 
correlations ranging from 0.48 - 0.85 (table 2). Test-retest reliability for the total score of this 
scale was 0.94 (ICC), whereas the K
w
 for items ranged from 0.82 to 0.90. Cronbach α for 
the DS subscale was 0.91, with corrected item-scale correlations between 0.55 and 0.88. The 
ICC for the total score of DS was 0.89, with the K
w
 for items ranging from 0.49 - 0.82.
Validity. The scores on all items of both parts of the SCOPA-SLEEP differed 
signiﬁcantly between patients and controls, with the exception of item NS1 (difﬁculty 
falling asleep) (table 3). Responses to seven of the eight additional questions also differed 
signiﬁcantly between patients and controls (all p-values < 0.001). The one exception again 
concerned sleep initiation, with both groups indicating similar amounts of time before falling 
asleep. Sumscores of patients and controls differed signiﬁcantly on all included sleep scales 
(table 4). The correlation between NS and the PSQI total score in the patient group was 0.83 
(p < 0.001) and the correlation with the separate subscales of the PSQI ranged from 0.38 to 
0.73 (all p-values < 0.001). The correlation between NS and the ‘global sleep quality score’ 
was 0.85 (p < 0.001), whereas this was 0.78 (p < 0.001) for the PSQI with the global score. 
The correlation between the DS scale and the ESS in the patient group was 0.81 (p < 0.001). 
No signiﬁcant differences were found in the scores of patients grouped by disease severity for 
any of the four scales (ANOVA). The relation with disease duration displayed similar results, 
with low and insigniﬁcant correlations. There were no signiﬁcant differences in any of the 
four scale scores between patients who used levodopa and those who did not. We also found 
no signiﬁcant correlation between the levodopa dose and any of the scale scores in those 
patients that took levodopa. Scores on both scales that evaluated DS were higher for patients 
taking dopamine-receptor agonists, with differences reaching signiﬁcance in the ESS (8.8 vs 
5.9; p = 0.04) but not in the DS (5.9 versus 4.1; p = 0.07). Subjects who used sleep medication 
had signiﬁcantly higher NS and PSQI scores in both the patient and the control group (p < 
0.001), but differences in DS and ESS scores were not signiﬁcant. 
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Table 3: SCOPA-SLEEP item scores, median (interquartile range) 
Patients Control P-value P-adj1
Night-time Sleep  (NS)
1. difﬁculty falling asleep 0 (1) 0 (1) 0.9592 0.771
2. been awake too often 1 (2) 1 (1) 0.0032 < 0.0012
3. lying awake too long 1 (2) 0 (1) < 0.0012 < 0.0012
4. waking too early 1 (2) 0 (1) < 0.0012 < 0.0012
5. had too little sleep 1 (2) 0 (1) < 0.0012 < 0.0012
‘overall sleep quality’ (0-6) 2 (2) 1 (1) < 0.0012 < 0.0012
Daytime sleepiness (DS)
1.  falling asleep unexpectedly 1 (2) 0 (1) < 0.0012 < 0.0012
2. falling asleep while sitting 1 (2) 0 (1) < 0.0012 < 0.0012
3. falling asleep watching TV 1 (1) 0 (1) < 0.0012 < 0.0012
4. falling asleep while talking 0 (0) * < 0.0012 < 0.0012
5. difﬁculty staying awake 1 (1) 0 (1) < 0.0012 < 0.0012
6. sleepiness problematic 0 (1) 0 (0) < 0.0012 < 0.0012
Other sleep parameters
1. n (%) using sleep medication 27 (19) 7 (7) 0.0024 < 0.0012
2. sleep initiation time (minutes) 22 19 0.5344 0.71
3. time awake per night (hours) 1.9 0.6 0.0063 0.005
4. actual sleep per night (hours) 6.3 7.0 0.0013 0.007
5. sleep in daytime (minutes) 34 11 < 0.0013
6. median (IQ range) planned naps 2 (3) 0 (2) < 0.0012
7. median (IQ range) unplanned naps 1 (2) 0 (1) < 0.0012
8. median (IQ range) unexpected sleep 0 (1) 0 (0) < 0.0012
*all controls scoring 0; 1 univariate analysis of variance, adjusted for age and sex; 2Mann-Whitney-U  3t-test; 4Chi-
square test
If the proposed PSQI cut-off value (5/6) was used to discriminate between good and 
bad sleepers, 106 subjects (29 controls and 77 patients, ie, 43.8 % of the total sample) were 
considered poor sleepers. Using this PSQI cut-off as an external criterion for the NS subscale, 
resulted in an area under the receiver operating characteristic (ROC) of 0.90, with an optimal 
cut-off at 3/4, yielding a sensitivity of 0.82 and speciﬁcity of 0.84. Since we considered the 
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proportion of subjects with poor sleep by this criterion in both groups exceptionally high, we 
also used responses to the ‘global sleep quality’ item as a criterion. This learned that only 32 
subjects (3 controls, 29 patients) actually considered themselves poor sleepers, a ﬁnding that 
agrees better with the literature.1;26;27 If this global item was used to separate patients who 
slept badly (scores 4 – 6) from those who did not (scores 0 – 3), the best cut-off point for 
the NS subscale was 6/7, with an area under the ROC curve in patients of 0.94. This cut-off 
value showed a sensitivity of 0.97 and a speciﬁcity of 0.80. Using this same ‘global sleep 
quality criterion’ for the PSQI, suggested that a cut-off of 8/9 would be more appropriate, 
both in patients and in all subjects, resulting in an area under the ROC curve of 0.91, with a 
sensitivity of 0.93 and a speciﬁcity of 0.76.
Table 4: Sumscores of patients and controls
Patients Controls P-adj1 CV2
mean (SD) SCOPA – NS (night-time sleep) 4.9 (4.0) 2.8 (2.7) < 0.001 0.82
mean (SD) Pittsburgh Sleep Quality Index 7.2 (4.3) 4.5 (3.3) < 0.001 0.70
mean (SD) SCOPA – DS (daytime sleepiness) 5.2 (4.1) 2.1 (2.0) < 0.001 0.79
mean (SD) Epworth Sleepiness Scale 7.9 (5.3) 4.1 (3.2) < 0.001 0.67
1univariate analysis of variance, adjusted for age and sex; 2Coefﬁcient of Variation, i.e., the standard deviation of 
the score divided by the mean of the score; higher values of CV indicate better ability to detect differences between 
individuals
Three controls and 38 patients had an ESS score of at least 11, whereas none of the 
controls and 16 of the patients scored 16 or higher. Using the cutoff value of 10/11 to separate 
persons with excessive DS from those without, indicated an optimal cut-off value of 4/5 for 
the SCOPA-DS. The area under the ROC curve was 0.93, with a sensitivity of 0.90 and a 
speciﬁcity of 0.82.
Factor analysis on the SCOPA-NS revealed one factor, accounting for 68.1 % of 
the variance. For the DS subscale, one factor emerged, explaining 69.1 % of the variance. 
The factor analysis of the PSQI was performed on the seven subscales, which produced two 
factors accounting for 58.7 % of the variance, with the sleep-pattern-related items (quality, 
duration, efﬁciency, and latency) loading on one factor, and daytime dysfunction and sleep 
disturbances loading on the other. The ESS also revealed two factors, together explaining 
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63.4 %. Items that addressed the more private situations at home (items 1, 2, 5, and 7) loaded 
on one factor, whereas items that evaluated more ‘public’ situations (car, public places, 
talking to someone; items 3, 4, 6, and 8) loaded on the other. 
The CV of both the NS and the DS scales were higher than those of the PSQI and 
the ESS (table 4). 
Discussion
We developed a short questionnaire for the assessment of sleep problems consisting 
of two scales, one that evaluates NS and one that assesses DS and assessed its performance 
in a population of patients with PD. The scales displayed good acceptability, and substantial 
ﬂoor and ceiling effects were absent. Both scales revealed good internal consistency and 
reproducibility, indicating reliability for both scales. The high reliability of the scales 
allows the use at the level of the individual patient.28 Patients with PD had signiﬁcantly 
higher scores than controls on both scales. Correlation with other scales that address similar 
constructs was high, giving support to the construct validity of the SCOPA-SLEEP. The 
factor analysis revealed one factor for each SCOPA scale, indicating that the scales each 
measure one construct, therewith justifying the calculation of sumscores. The CV of both 
SCOPA scales were higher than those of the PSQI and the ESS, indicating a better ability 
to detect differences between individuals. Responsiveness of the SCOPA scales, however, 
remains to be evaluated.
Assessment of NS sleep. Studies in other populations showed that the PSQI has 
adequate reliability and validity.10;29-32 For internal consistency, this was conﬁrmed by the 
results of our study. The scale has previously been used in PD.33-35 Some comments regarding 
the PSQI are in order, however. First, the content validity of the PSQI may be questioned, 
especially with respect to use in PD. The PSQI evaluates daytime dysfunction, but problems 
in this area can be caused by PD as well as other diseases and do not necessarily relate 
to nocturnal problems. The score on the daytime dysfunction subscale is made up of two 
items, ie, ‘enthusiasm to get things done’ (which could be affected by PD but also by other 
diseases such as depression) and ‘trouble staying awake’ (which could be caused by PD or 
by the effect of antiparkinsonian medication). Second, the incorporation of ‘trouble staying 
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awake’ and taking sleep medication’ in the total score is questionable. These items address a 
clearly different construct than the other items that evaluate aspects of sleep pattern. This is 
partially conﬁrmed by the factor analysis, in which daytime dysfunction (together with sleep 
disturbances) loads on one factor, whereas the other, sleep-pattern-related items (quality, 
duration, efﬁciency, and latency) load on the other. Third, calculating the total score of 
the PSQI is time consuming, which makes it less suitable for clinical application. These 
arguments favor the use of the SCOPA-NS in patients with PD. Additionally, if the PSQI is 
used in patients with PD, a higher cut-off may be more appropriate.
Assessment of DS. Studies in other populations have shown that the internal 
consistency of the ESS is adequate.15;36-38 The scale has been shown to discriminate successfully 
between healthy controls and patients with sleep disorders, but test-retest reliability has not 
been assessed among patients and therefore remains uncertain.19;37;39 Responsiveness of this 
scale has not yet been assessed.19;37;39 The ESS has frequently been used in PD.8;9;33;40-47 Two 
additional comments regarding the use of the ESS are needed. First, patients are asked to rate 
the chance of dozing, without actually having to have had the experience of dozing off in that 
particular situation. Three of the situations described in the ESS (sitting inactive in a public 
place, as a passenger in a car for an hour without a break, and in a car while stopped for a 
few minutes) may actually be experienced infrequently by the more severely affected or older 
patients, which may further compromise the patient’s appraisal of the situation. Second, in 
both the patient and the control group, two factors emerged, suggesting that the scale does not 
measure one construct. The SCOPA-DS may therefore be preferred in this population, since 
it does not have the aforementioned objections.
The ﬁrst disease-speciﬁc sleep scale in PD, the Parkinson’s Disease Sleep Scale,11 
was published very recently and evaluates various aspects of nocturnal sleep problems. 
Unfortunately, this publication appeared after we ﬁnished our data collection, and hence this 
scale was not included in our study. A direct comparison of these two disease-speciﬁc scales 
would have produced valuable information. The Parkinson’s Disease Sleep Scale includes 
15 items that evaluate overall sleep quality (1 item), insomnia (2 items), potential reasons 
of sleep disturbances (6 items), motor symptoms (4 items), sleep refreshment (1 item), and 
daytime dozing (1 item). Patients indicate on a 10-cm visual analog scale how well they 
slept or how often the described items applied to them, based on their experience during 
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the past week. On face value, the scale appears to measure various constructs. A thorough 
clinimetric evaluation has not yet been published. Internal consistency and factor analysis 
were not reported, therewith ruling out the possibility of judging whether the calculation 
of sumscores is justiﬁed. The reproducibility of this scale seems adequate, but was only 
assessed in 15 patients. The relation with other scales was assessed only by calculating the 
correlation between one item of this scale (unexpectedly falling asleep during the day) and 
a scale that addresses daytime sleepiness (ESS) but not with scales that evaluate nocturnal 
sleep problems. 
In conclusion, sleep problems occur frequently in PD and deserve appropriate 
attention. The SCOPA-SLEEP scale is a valid, reliable, and short scale that can be adequately 
used to evaluate sleep problems in this population. Items in the SCOPA-SLEEP are not 
disease speciﬁc, and therefore this instrument may also be applicable to other populations. 
Future studies that assess its performance in other populations are recommended.
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Appendix  - SCOPA SLEEP scale  
Aim of the questionnaire
By means of this questionnaire, we would like to ﬁnd out to what extent in the past month you have 
had problems with sleeping. Some of the questions are about problems with sleeping at night, such 
as, for example, not being able to fall asleep or not managing to sleep on. Another set of questions 
is about problems with sleeping during the day, such as dozing off (too) easily and having trouble 
staying awake.
First read these instructions before you answer the questions!
Place a cross in the box above the answer which best reﬂects your situation. If you wish to change an 
answer, ﬁll in the ‘wrong’ box and place a cross in the correct one. If you have been using sleeping 
tablets, then the answer should reﬂect how you have slept while taking these tablets.
NS: Night-time sleep problems 
response options: not at all – a little – quite a bit – a lot
     In the past month, …
1.  … have you had trouble falling asleep when you went to bed at night?
2.  … to what extent do you feel that you have woken too often?
3.  … to what extent do you feel that you have been lying awake for too long at night?
4.  … to what extent do you feel that you have woken up too early in the morning?
5.  … to what extent do you feel you have had too little sleep at night?
Overall, how well have you slept at night during the past month?
response options: very well – well – rather well – not well but not badly - rather badly – badly - very 
badly
DS: Daytime sleepiness
response options: never – sometimes – regularly – often
1.  How often in the past month have you fallen asleep unexpectedly either during the day or in the 
evening?
2.  How often in the past month have you fallen asleep while sitting peacefully?
3.  How often in the past month have you fallen asleep while watching TV or reading?
4.  How often in the past month have you fallen asleep while talking to someone?
5.  In the past month, have you had trouble staying awake during the day or in the evening?
6.  In the past month, have you experienced falling asleep during the day as a problem?
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Abstract
The aim of this study was to assess the accuracy of an interview-based assessment 
of comorbidity, in patients with PD. The Cumulative Illness Rating Scale-Geriatric (CIRS-
G) was completed (1) in an interview with 31 PD patients and their caregivers, and (2) by 
reviewing the patient’s medical charts from their general practitioners. Based on the interview, 
all patients had some comorbidity, 84% had one or more moderate comorbid diseases. The 
most frequently affected organ systems were “lower gastrointestinal” and “genitourinary”. 
The mean ± S.D. total score of the interview-based (chart-based) CIRS-G was 6.9 ± 3.8    (7.6 
± 3.5) with a mean of 4.3 ± 1.9 (5.0 ± 1.9) affected organ systems and a mean of    2.1 ± 1.7 
(2.3 ± 1.6) organ systems with at least moderate comorbidity per patient. The agreement 
(intraclass correlation coefﬁcients) between the interview-based and chart-based assessments 
for the six summary scores ranged from 0.69-0.81. The agreement for the 14 organ systems 
ranged from 0.13-1.00 (weighted kappa's), 12 had a K
w
 above 0.40 (moderate agreement). 
The comorbidity summary scores had a moderate correlation with age and disability. The 
interview-based assessment of the CIRS-G is easy to apply and is an accurate method to 
assess comorbidity in patients with PD.
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Comorbidity refers to one or more distinct diseases among people with an index-
disease1 and has rarely been studied in Parkinson’s disease (PD). Although mortality in PD 
has been related to respiratory tract infection or cerebrovascular diseases,2;3 the majority of 
comorbid diseases have greater impact on disability than on mortality (e.g. osteoarthritis);4 
consequently, patients with comorbidity have higher resource use and costs.5 Comorbidity 
will be of inﬂuence during the assessment of PD-related disabilities,6 therefore, a comorbidity 
index should be included when studying disease course, prognosis, outcome of treatment, 
or costs. The Cumulative Illness Rating Scale-Geriatric (CIRS-G)7 is a useful instrument 
to evaluate comorbidity in relation to disability. However, the CIRS-G has been assessed 
mainly in institutionalized elderly by reviewing their charts, which is time consuming and 
involves higher costs. The aim of this study was to assess the accuracy of an interview-based 
assessment of the CIRS-G for assessing comorbidity in outpatients with PD. This report is 
part of a large research project, the SCales for Outcomes in PArkinsons’s disease (SCOPA), 
in which practical, reliable and valid instruments for all relevant aspects of PD are selected 
or developed. 
Methods
The CIRS was initially designed by Linn and collagues8 and adapted for a geriatric 
population by Miller.7 The severity of comorbid diseases is rated for 14 organ systems. The 
worst problem in an organ system is rated on a scale from 0 to 4 (0=none; 4=extremely severe/
immediate treatment required/end organ failure/ severe impairment in function). According 
to Miller and coworkers,7 ﬁve summary scores can be calculated and we calculated an 
additional summary score: the number of organ systems with at least moderate comorbidity 
(organ system score of ≥2). Both the inter-rater reliability7 and test-retest reliability9 of the 
CIRS-G have been reported as good and the CIRS-G has been shown to have good predictive 
validity,10 discriminative validity7;11 and to correlate fairly with age, medication usage, 
functional disability and physicians’ global estimates of medical burden.7;12;13
Patients were randomly selected from the database of the outpatient movement 
disorders clinic of the Leiden University Medical Center, the Netherlands. They all had a 
general practitioner (GP) in or near Leiden, and fulﬁlled the United Kingdom Parkinson’s 
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Disease Society Brain Bank criteria (UKPDSBB) for idiopathic PD.14 A letter containing 
information about the purpose and the design of the study was sent to 41 PD patients. One 
week later, these patients were contacted by phone and asked to participate in this study. The 
assessment then took place in the hospital or at home for those unable to travel. Patients were 
asked to list their current medication, and the presence of a partner or caregiver during the 
interview was encouraged. The patients that participated in this study gave informed consent 
and written permission to the researchers to review their GP chart.
A trained researcher conducted a structured interview according to the guidelines 
from the manual of the CIRS-G.15 PD itself was not rated as comorbid disease. Patients were 
evaluated with respect to demographic characteristics, the Hoehn and Yahr stage (H&Y)16 for 
disease severity, the Mini Mental State Examination (MMSE)17 for cognitive function, the 
Schwab and England (S&E)18 and the Activities of Daily Living (ADL) section of the SPES/
SCOPA (Short Parkinson’s Evaluation Scale/SCales for Outcomes in PArkinson’s disease)19 
to evaluate functional status. At 1 to 3 weeks after the interview, the researcher completed 
the CIRS-G based on information obtained from the GP chart. The local medical ethical 
committee approved the study protocol. 
Statistical analysis
Means and standard deviations (SD) for the six summary scores were calculated for 
the interview-based and chart-based CIRS-G. Wilcoxon test was used to test for differences 
between the interview-based and chart-based summary scores. Weighted kappa values (K
w
) 
and percentage agreement were used to calculate the agreement between the interview-based 
and chart-based scores per organ system. Intraclass correlation coefﬁcients (ICCs) were used 
to calculate the agreement for the six summary scores. Spearman correlation was used for the 
correlation of the interview-based CIRS-G summary scores with age, disease duration, H&Y, 
S&E, and the SPES/SCOPA-ADL. Spearman correlation was also used for the correlation of 
the difference between the interview and chart-based total score with the MMSE.
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Results
A total of 31 patients with PD (18 men) participated in this study, a response rate 
of 76%. The mean ± SD age of the patients was 70.0 ± 8.6 years, with a mean disease 
duration of 8.7 ± 6.2 years (Table 1). Chart reviews were performed at 16 GP ofﬁces. The 
mean time interval between the patient interview and the chart review was 13 ± 8 days. All 
patients had some comorbidity, and based on the interview, 84% had one or more moderate 
comorbid diseases and 15% had severe comorbidity. The mean total score of the interview-
based CIRS-G was 6.9 ± 3.8 with a mean of 4.3 ± 1.9 organ systems endorsed, and a mean of 
2.1 ± 1.7 organ systems with at least moderate comorbidity (Table 2). The mean total score 
of the chart-based CIRS-G was 7.6 ± 3.5 with a mean of 5.0 ± 1.9 affected organ systems 
and a mean of 2.3 ± 1.6 organ systems with at least moderate comorbidity (Table 2). Chart-
based scores were higher than the interview-based summary scores; these differences were 
signiﬁcant for the total score and the number of organ systems endorsed. 
Table 1: Patient characteristics 
Patients 31
Gender (% m) 18 (58%)
Age (yr) 70.0 ± 8.6
Disease duration (yr) 8.7 ± 6.2
No. of patients on levodopa (%) 25 (81%)
Daily levodopa  (mg) 752.9 ± 486.5
No. of patients on DA (%) 16 (52%)
MMSE 26.5 ± 3.0
S&E 76.5 ± 13.8
SPES/SCOPA-ADL 8.7 ± 4.0
H&Y distribution (I, II, II, IV, V) 3 / 11 / 9 / 7 / 1
Data presented as mean ± SD; DA, Dopamine agonists; MMSE, Mini Mental State Examination; S&E, Schwab 
and England; SPES/SCOPA-ADL, Short Parkinson Evaluation Scale/SCales for Oucomes in PArkinson's disease-
Activities of Daily Living; H&Y, Hoehn and Yahr; % m, percentage men.
 The ICCs of the six summary scores ranged from 0.69 to 0.81. No comorbidity 
was rated as “extremely severe”; therefore no further analysis was done of this summary 
score. The agreement between the interview and the chart was better for moderate and 
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severe comorbidities, compared to mild comorbidities.
Table 2: CIRS-G Summary scores and agreement
Interview Chart ICC
Total score* 6.9 ± 3.8 7.6± 3.5 0.80
Organ systems ≥ 1* 4.3 ± 1.9 5.0 ± 1.9 0.69
Organ systems ≥ 2 2.1 ± 1.7 2.3 ± 1.6 0.81
Organ systems = 3 0.2 ± 0.6 0.2 ± 0.5 0.79
Organ systems = 4 0.0 ± 0.0 0.0 ± 0.0 -
Severity index 1.5 ± 0.3 1.5 ± 0.3 0.71
* Wilcoxon test signiﬁcant (p≤ 0.05); ICC, Intra Class Correlation Coefﬁcient (two way mixed model); Severity 
Index, the Total Score divided by the number of affected organ systems; CIRS-G, Cumulative Illness Rating Scale-
Geriatric
Based on the interview, more than half of the patients had problems in the lower 
gastrointestinal and genitourinary system (Table 3). The K
w
s of the scores per organ system 
ranged from 0.13-1.00. According to the criteria of Landis and Koch,20 a K
w
 above 0.40 
reﬂects moderate agreement. Two organ systems had a K
w
 less than 0.40: respiratory (0.13) 
and renal (0.21). However, the percentage agreement between the interview and chart for 
these organ systems were 68% and 84%. In general patients reported less comorbidities 
during the interview than were present in their charts, and especially omitted signiﬁcant 
problems from the past. Examples of missed information were: hypertension, a history of 
ulcers or transient ischemic attacks.
CHAPTER 8
121
Table 3: Frequency and the (dis)agreement of the CIRS-G organ system scores (N = 31)
Organ systems
Freq 
(%)
K
w
Interview 
lower (%)
Agree (%)
Interview 
higher (%)
Heart 39 0.59 13 68 19
Vascular 39 0.79 3 81 16
Hematopoetic 3 1.0 - 100 -
Respiratory 29 0.13 19 68 13
Eyes, ears, nose, throat and larynx 48 0.92 6 90 3
Upper Gastrointestinal 16 0.52 16 77 6
Lower Gastrointestinal 55 0.90 3 87 10
Liver 29 0.84 3 90 6
Renal 16 0.21 3 84 13
Genitourinary 52 0.61 23 65 13
Musculoskeletal/ Integument 48 0.75 19 71 10
Neurological 13 0.42 19 74 6
Endocrine/Metabolic and breast 16 1.0 - 100 -
Psychiatric 23 0.74 13 87 -
Freq (%), interview-based affected organ systems (organ system score ≥ 1); K
w,
 weighted kappa (quadratic weight) 
of interview-based and chart-based organ system scores; CIRS-G, Cumulative Illness Rating Scale-Geriatric
The mean of the MMSE was 26.5 ± 3.0, of which four patients had an MMSE score 
≤ 23 (ranging from 18-22). The interview-based CIRS-G scores deviated more from the chart-
based scores in patients with lower MMSE scores, but this deviation was not signiﬁcant. The 
Spearman correlation between the MMSE score and the difference in score between the 
interview-based and chart-based CIRS-G total score was –0.24. The interview-based total 
score showed a moderate correlation with age (0.35) and SPES/SCOPA-ADL (0.31) a low 
correlation with H&Y (0.20), and did not correlate with disease duration, and S&E.
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Discussion
In this study all patients had some comorbidity, indicating the importance of assessing 
this aspect. The interview-based total score was 6.9, and patients reported on average 4.3 
affected organ systems, most often in lower gastrointestinal (55%), genitourinary (52%), 
musculoskeletal/integument (48%) and eyes, ears, throat and larynx (48%). Compared 
to Miller and collagues, the patients in our study are rated between healthy elderly with 
a mean CIRS-G total score of 4.5 with 3.7 organ systems endorsed, and patients from a 
multidisciplinary geriatric medical clinic with a mean total score of 10.6 with 5.4 affected 
organ systems.7 
This study demonstrates that accurate information on comorbidity in patients with 
PD can be obtained using an interview-based CIRS-G; adequate accuracy was demonstrated 
for the organ systems, and good agreement for the summary scores. Similar accuracy of 
patients’ self-reports was found in a study comparing GP’s information of the presence of 
8 speciﬁc chronic diseases in elderly patients.21 Although patients both under-report and 
over-report comorbidities, they usually reported less disorders than are found by reviewing 
their GP chart; the agreement between interview and chart being higher for the more severe 
disorders. Mild current disorders or signiﬁcant past problems are less frequently reported 
by patients. These problems are probably of less inﬂuence to the patient’s functioning and, 
consequently, the more relevant comorbidities will remain. Agreement on organ system scores 
was lower than on summary scores, especially in respiratory and renal systems. Information 
in the charts concerning past problems, such as bronchitis, or current problems that did not 
need treatment, such as mild emphysema, were not reported by the patient. Alternatively, 
patients reported problems like pneumonia, tuberculosis or kidney stones that were not in the 
GP charts. This may partly reﬂect the inaccuracy of the charts, or a change of GP. To obtain 
useful information in an interview, questions should be asked about speciﬁc diseases, visits 
to specialists, diagnostic tests, surgery, and the use of medication. 
An advantage of the CIRS-G is the resemblance to clinical practice: all disorders, 
and not only the most prevalent or most life-threatening disease, can be rated in one of the 
organ systems, taking into account both the presence and the severity of the disease.22 The 
CIRS-G is aimed at a geriatric population, but the structure and rating of relevant body 
systems also allows its use in younger PD patients. Although chart review probably yields the 
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most valid data, it is not a true gold standard for comorbidity, as its accuracy depends on the 
completeness of documentation. The completeness of data by patient interview depends on 
the ability of patients to adequately recall the diseases they suffer from. To reduce the effect 
of potential problems, patients were told in advance of the purpose of this study, asked to list 
all their current medication, and partners or caregivers were encouraged to be present during 
the assessment. Patients with more cognitive problems showed more differences between 
their interview-based and chart-based CIRS-G scores. Hence, when assessing comorbidity in 
demented PD patients, a chart review should be used.
A shortcoming of this study may be that one researcher interviewed all the patients 
and reviewed their medical charts 14 days later. The researcher, therefore, was not blind 
to the outcomes, and a slight overestimation of agreement cannot be ruled out. However, 
retaining all the information would have been difﬁcult because of the time interval between 
the two ratings and the fact that several patients were assessed in the same period.
In most trials, relevant comorbidity is an exclusion criterion: therefore, these study 
populations differ substantially from usual care populations of elderly PD patients. In study 
designs focusing on disability or mortality, patients with signiﬁcant comorbidity should be 
included and a measure of comorbidity should be incorporated. This can be achieved by 
an interview-based assessment with the CIRS-G, which is easy to apply and is an accurate 
method to assess comorbidity in PD.
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In this thesis the results are presented of the clinimetric evaluation and development of rating 
scales that assess domains that are all part of the disablement process in PD. 
Chapter 1 is an outline of the broad spectrum of affected clinical domains in PD and 
the marked heterogeneity within the PD population. For the description of the various domains 
in PD, the disablement process was used. The disablement process is a sociomedical model 
that describes the pathway from pathology to disability and incorporates extra-individual 
and intra-individual factors that speed up or slow down the disablement. The evaluation of 
patients with PD in the different domains of the disablement process requires a broad range 
of assessment scales. Each of these scales should comply with clinimetric criteria: a high 
level of reliability, validity, and responsiveness. The aims of this thesis were to construct a 
disease-speciﬁc model of PD encompassing the relevant domains of impairment, disability, 
global health and intra-individual and extra-individual factors that act on the pathway from 
pathology to disability, and to assign clinimetrically sound rating scales to these domains.
The objective in chapter 2 was to evaluate the responsiveness of items of the 
Activities of Daily Living (ADL) and the Motor section of the Uniﬁed Parkinson’s Disease 
Rating Scale (UPDRS). A standardized Response Mean (SRM) was calculated per item 
using data from four trials (n = 376) that randomized patients with early PD to dopamine 
agonist (DA) monotherapy or placebo. In the ADL section the SRMs ranged from -0.04 
(no effect) to -0.50 (moderate effect). Hand functions were the most responsive ADL items, 
with “handwriting” showing the largest response. Self-assessed symptoms were the least 
responsive. In the Motor section, SRMs ranged from -0.09 to -0.60, with bradykinesia items 
showing the largest response, especially the item “ﬁnger taps”. The tremor items showed 
the smallest response, but “rest tremor arms” was much more responsive than “rest tremor 
of the head and legs” or “postural tremor”. SRMs in the placebo group ranged from 0.08 to 
-0.21 in the ADL section and from -0.03 to -0.35 in the Motor section. ADL and Motor items 
had comparable and mostly small effect-sizes. The most responsive items were in the ADL 
section hand functions and in the Motor section bradykinesia items. A more responsive ADL 
section would omit the self-assessed symptoms and the Motor section would retain, of the 
tremor items, only “rest tremor arms”.
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Chapter 3 set out to determine which test for postural instability in PD was reliable, 
valid and easy to perform in a clinical setting. Forty-two PD patients and 15 control subjects 
participated in this study. The PD patients were, based on the results of a structured interview, 
divided into PD-unstable (N=22) and PD-stable (N=20) groups. Several variants of the 
retropulsion test, with differences in execution and scoring, were executed. Responses were 
scored on ﬁve different rating scales (according to Nutt, Bloem, Pastor, the Uniﬁed Parkinson’s 
Disease Rating Scale (UPDRS) and the Short Parkinson Evaluation Scale (SPES)). These 
scores were compared with steady-stance positions. The inter-rater reliability was high for 
most ratings, weighted kappa’s ranged from 0.63 for the UPDRS rating, to 0.98 for both the 
Pastor rating and steady-stance positions. Most ratings distinguished between the groups. 
However, the Nutt rating had the highest overall predictive accuracy, with a sensitivity of 
0.63 and a speciﬁcity of 0.88. To conclude, the most valid test for postural stability in PD 
was an unexpected shoulder pull, executed once, with taking more than two steps backwards 
considered abnormal. This retropulsion test is easy to use in a clinical setting.
Chapter 4 evaluates the reliability and validity of the SPES/SCOPA, a short scale 
developed to assess motor function in patients with Parkinson’s disease (PD). Eighty-ﬁve 
patients with PD were assessed with the SPES/SCOPA, the Uniﬁed Parkinson’s Disease 
Rating Scale (UPDRS), the Hoehn and Yahr (H&Y) scale, and the Schwab and England 
(S&E) scale. To evaluate inter-rater reliability, 34 patients were examined twice by two 
different assessors who were blinded to each other’s scores and test executions. Additionally, 
six items of the motor impairment section of the SPES/SCOPA were assessed in nine patients 
and recorded on videotape, to evaluate inter-rater and intra-rater reliability. The test-retest 
reliability of the sum scores in the clinical assessments was high for all subscales of the 
SPES/SCOPA. Inter-rater reliability coefﬁcients for individual items ranged from 0.27 to 0.83 
in the motor impairment section, from 0.58 to 0.82 in the activities of daily living section, 
and from 0.65 to 0.92 in the motor complications section. Inter-rater reliability of the motor 
items in the video assessments ranged from 0.70 to 0.87 and intra-rater reliability from 0.81 
to 0.95. The correlation between related sub-scales of the SPES/SCOPA and UPDRS were 
all higher than 0.85, and both scales revealed similar correlations with other measures of 
disease severity. The mean time of completion of the scales differed signiﬁcantly (p<0.001) 
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and measured 8.1 (SD 1.9) minutes for the SPES/SCOPA and 15.6 (SD 3.6) minutes for the 
UPDRS. The conclusion is that the SPES/SCOPA is a short, reliable and valid scale that can 
be used in both research and clinical practice.
The development of a questionnaire that assesses autonomic symptoms in patients 
with PD was described in chapter 5, and its reliability and validity were evaluated. Based 
on the results of a postal survey in 46 PD patients, 21 multiple system atrophy patients and 
8 movement-disorders specialists, items were included according to their frequency, burden 
and clinical relevance. The questionnaire was then evaluated in 140 PD patients and 100 
control subjects, and test-retest reliability was established in a sample of 55 PD patients. 
The SCOPA-AUT consists of 25 items, assessing the following regions: gastrointestinal 
(7), urinary (6), cardiovascular (3), thermoregulatory (4), pupillomotor (1) and sexual (2 for 
men and 2 for women) dysfunction. Test-retest reliability was good. Autonomic problems 
increased signiﬁcantly with increasing disease severity for all autonomic regions, except 
sexual dysfunction. We conclude that SCOPA-AUT is a reliable and valid questionnaire to 
evaluate autonomic dysfunction in PD.
Chapter 6 is a description of the evaluation of the validity, reliability and potential 
responsiveness of the Beck Depression Inventory (BDI) in patients with Parkinson’s disease 
(PD). This study was carried out in two parts. Part 1: ninety-two patients with PD underwent 
a Structured Clinical Interview for DSM-depression and based on this patients were 
considered depressed (PD-D) or non-depressed (PD-ND), subsequently patients ﬁlled in the 
BDI. Part 2: a postal survey consisting the BDI was performed in 185 PD patients and 112 
controls. Test-retest reliability was assessed in 60 PD patients. The factor analysis revealed 
a cognitive-affective and a somatic factor. Cronbachs α for the BDI was 0.88. Mean BDI 
indicated signiﬁcant differences (p<0.001) between the PD and control group, between the 
PD-ND and PD-D group and between PD-ND and control group. In part 1, the ROC-curves 
showed that the AUC for the total BDI was 0.88. A cut-off was calculated for the BDI (14/15) 
that had the highest sum of sensitivity (0.71) and speciﬁcity (0.90). In part 2, the test-retest 
reliability for the BDI total score was 0.89 (Intraclass Correlation Coefﬁcient). The smallest 
real difference (SRD) was 3.3 for the total BDI. To conclude, the BDI is a valid, reliable 
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and potential responsive instrument to assess the severity of depression in PD, however an 
adjusted cut-off is recommended. 
The development of a short and practical scale that evaluates nighttime sleep and 
daytime sleepiness (SCOPA-SLEEP) was outlined in chapter 7. This scale was developed 
for research in Parkinson’s disease, but may be of value for other somatic diseases. One-
hundred-and-forty-three patients with PD and 104 control subjects participated in the postal 
survey, which included four instruments, the SCOPA-SLEEP nighttime sleep (5 items) and 
daytime sleepiness (6 items), the Pittsburgh Sleep Quality Index and the Epworth Sleepiness 
Scale. The reliability of the scale was high: internal consistency of the nighttime sleep and 
daytime sleepiness scales were 0.88 and 0.91, respectively (Cronbach alpha), and test-
retest reliabilities were 0.94 and 0.89, respectively (intraclass correlation coefﬁcient). Scale 
scores differed signiﬁcantly between patients and control subjects (p < 0.001). The construct 
validity was assessed by correlations with scales that addressed similar constructs. The 
correlation between the nighttime sleep scale and the Pittsburgh Sleep Quality Index was 
0.83 (p < 0.001), and the correlation between the daytime sleepiness scale and the Epworth 
Sleepiness Scale was 0.81 (p < 0.001). Factor analysis revealed one factor each for both 
scales, indicating that the scales measure one construct, which justiﬁes the calculation of sum 
scores. The coefﬁcient of variation of both the nighttime sleep and daytime sleepiness scale 
was higher than that of the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale, 
indicating a better ability to detect differences between individuals. The SCOPA-SLEEP is a 
reliable and valid instrument for assessing nighttime sleep and daytime sleepiness in patients 
with Parkinson’s disease.
The aim of chapter 8 was to assess the accuracy of an interview-based assessment 
of comorbidity in patients with PD. The Cumulative Illness Rating Scale-Geriatric (CIRS-
G) was completed (1) in an interview with 31 PD patients and their caregivers, and (2) by 
reviewing the patients’ medical charts, obtained from their general practitioners. Based on 
the interview, all patients had some comorbidity, 84% had one or more moderate comorbid 
diseases. The most frequently affected organ systems were “lower gastro-intestinal” and 
“genito-urinary”. The mean ± SD total score of the interview-based (chart-based) CIRS-G 
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was 6.9 ± 3.8 (7.6 ± 3.5) with a mean of 4.3 ± 1.9 (5.0 ± 1.9) for affected organ systems and 
a mean of 2.1 ± 1.7 (2.3 ± 1.6) for organ systems with at least moderate comorbidity per 
patient. The agreement (intraclass correlation coefﬁcients) between the interview-based and 
chart-based assessments for the six summary scores ranged from 0.69 to 0.81. The agreement 
for the 14 organ systems ranged from 0.13 to 1.00 (weighted kappa's), 12 had a K
w
 above 
0.40 (moderate agreement). The comorbidity summary scores had a moderate correlation 
with age and disability. The interview-based assessment of the CIRS-G is easy to apply and 
is an accurate method for assessing comorbidity in patients with PD.
Concluding remarks
The disablement process is a useful model when studying the full spectrum and 
progression of PD. In this thesis a number of domains have been studied. The studies 
included in this thesis show that PD encompasses much more than motor problems alone. 
Sleep, depression, and autonomic disturbances are important domains of PD as well. The 
availability of reliable, valid and practical assessment instruments will facilitate the evaluation 
of these PD domains in both patient management and research. The relationship between 
PD and disability may be complicated by the presence of comorbidity. Comorbid diseases 
are prevalent and the results of many studies, in which patients with comorbid diseases are 
excluded, will not reﬂect the general PD population because of this exclusion. It is important 
thus, to consider the effect of comorbidity and include a measure of comorbidity when 
studying PD.
Although not included in this thesis, PD-speciﬁc assessments have also been 
developed and evaluated for the domains of cognition (SCOPA-COG),1 psychosocial 
disability (SCOPA-PS)2, a diary card for motor ﬂuctuations (SCOPA-DC) and costs (SCOPA-
COST). Furthermore, assessments for psychiatric complications and pain are currently being 
developed. Psychiatric complications will be assessed by means of a modiﬁed version of 
the Parkinson Psychosis Rating Scale (PPRS). The 6 initial items have been partly altered 
to improve the scoring. SCOPA-PAIN is an assessor-based questionnaire that evaluates the 
severity, duration and type of pain that patients have endured during the last month. All 
together, these complete the assessment instruments of the disablement process in PD.
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The model of the disablement process that was chosen in 1999 as a conceptual 
framework for the assessment of PD is currently less different from the WHO model developed 
in 2002 on the International Classiﬁcation of Functioning, Disability and Health (ICF).3 The 
ﬁrst model was chosen above the WHO-ICIDH model4 because it gave better insight in the 
disease, being a more dynamic model that includes social, psychological and environmental 
factors. The newly developed ICF is a classiﬁcation of health and health-related domains that 
also integrates biological, individual and social perspectives of health and might therefore be 
called a biopsychosocial model. The term functioning refers to all body functions, activities 
and participation, while disability similarly encompasses impairments, activity limitations 
and participation restrictions. Both functioning and disability are viewed as outcomes of 
interactions between health conditions (diseases, disorders, injuries) and contextual factors 
(both environmental and personal factors). The ICF and disablement process therefore have 
become more similar and both would provide a useful framework.   
The model of the disablement process in PD may be extended in the future. At 
each of the different levels of disease evaluation, domains may be added when it becomes 
apparent that they are part of the PD spectrum or complications of therapy. Although it is 
known that PD may have a severe impact on caregivers of patients5;6 we have not addressed 
this issue speciﬁcally in the model because the model is patient-based. The domain sleep is 
now evaluated as part of the impairments, but was considered a disability by Verbrugge and 
Jette2;7: ‘problems with the activity sleep at night’. Because sleep disturbances can also be 
considered an impairment and excessive daytime sleepiness (EDS) is clearly an impairment, 
the entire sleep disturbance domain was shifted to the impairments.
Future plans 
SCOPA is a complete and clinimetrically sound assessment tool for PD. The scales 
can be applied separately or as a whole. The assessment scales can, for instance, be used to 
evaluate the prevalence of PD-speciﬁc problems in community-based samples, or in trials 
to evaluate the effect of interventions. On the other hand, the application of the complete 
assessment tool will lead to better insight into the domain interrelations and possibly to the 
identiﬁcation of subgroups of PD. The assessment scales have all been evaluated for reliability 
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and validity, but in this thesis, responsiveness has only been evaluated in the UPDRS-ADL 
and motor examination. When the scales are used in a study evaluating change over time, it 
would be interesting to calculate the minimal clinically important differences (MCID) using 
anchor-based methods.
In May 2003 we started the SCOPA longitudinal project. In this study 400 PD 
patients are being evaluated annually using the SCOPA assessment scales. Patients are 
being evaluated for a period of 5 years. Age at onset of the disease and disease duration 
are important predictors in PD. Thus, to obtain a PD cohort where these predictors are 
adequately distributed, patients are stratiﬁed at baseline on the basis of age at onset of disease 
(< or > 50 yrs) and disease duration (< or > 10 years). Patient ﬁll out the self-assessed 
SCOPA instruments at home and the researcher-based SCOPA instruments are completed in 
the hospital. The aim of the SCOPA study is to identify subgroups of PD with differences 
concerning content and progression of the impairment domains. Individual differences in the 
interplay of the domains, and their role as intrinsic and extrinsic determinants will be studied. 
Knowledge on this subject is important for improving patient management, but may also play 
a role in establishing a better framework for the assessment of clinical features in therapeutic 
and translational research studies.
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In dit proefschrift worden de resultaten beschreven van de ontwikkeling van meetinstrumenten 
en het klinimetrische onderzoek van deze instrumenten, die samen alle domeinen van het 
“disablement process” van de ziekte van Parkinson (ZvP) bestrijken.
In hoofdstuk 1 wordt zowel de uitgebreidheid van klinische domeinen die voorkomen 
bij de ZvP als de heterogeniteit binnen de groep patiënten met de ZvP beschreven. De 
beschrijving van de verschillende domeinen wordt gedaan aan de hand van het “disablement 
proces”. Het “disablement proces” is een sociaal-medisch model dat het proces van ziekte 
naar beperkingen beschrijft. In dit model zitten ook de individuele en omgevingsfactoren 
die dit proces kunnen versnellen of vertragen. Een scala van meetinstrumenten is nodig 
om de verschillende domeinen bij patiënten met de ZvP te evalueren. Elk meetinstrument 
moet bovendien voldoen aan klinimetrische criteria: een hoog niveau van betrouwbaarheid, 
validiteit en responsiviteit. Het doel van dit proefschrift was ten eerste het ontwikkelen van 
een ziekte-speciﬁek model voor de ZvP, dat alle relevante domeinen omvat van stoornissen, 
beperkingen, algehele gezondheid en individuele en omgevingsfactoren die invloed hebben 
op het proces van ziekte naar beperkingen. Het tweede doel was om voor elk van deze 
domeinen een klinimetrisch goed meetinstrument te selecteren.
Het doel in hoofdstuk 2 is om de responsiviteit te onderzoeken van de items van de 
onderdelen Activiteiten van het Dagelijks Leven (ADL) en het Motorisch Onderzoek van de 
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS). Per item werd een Standardized Response 
Mean (SRM) berekend op basis van gegevens van vier gerandomiseerde geneesmiddelen 
studies (dopamine agonist (DA) of placebo) bij patiënten die in een vroeg stadium van de 
ZvP waren. In de ADL varieerden de SRMs van –0.04 (geen effect) tot –0.50 (matig effect). 
De handfuncties waren de meest gevoelige ADL items, waarbij “handschrift” de meeste 
verandering liet zien. Het minst responsief waren de zelf-beoordeelde symptomen. In het 
motorisch onderzoek varieerden de SRMs van –0.09 tot –0.60. Bradykinesie items lieten de 
meeste veranderingen zien, met name het item “repeterende vingerbewegingen”. Als groep 
lieten de tremor items de minste verandering zien, waarbij het item “rust tremor armen” veel 
responsiever was dan de items “rust tremor van het hoofd of de benen” of “houdingstremor”. 
SRMs in de placebo groep varieerden van 0.08 tot –0.21 in de ADL en van –0.03 tot –0.35 
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in het motorisch onderzoek. De conclusie is dat de items uit de ADL en motorische secties 
vergelijkbare (zowel gemiddelde als range) en veelal kleine effecten hebben. De meest 
responsieve items in de ADL zijn handfuncties en in het motorisch onderzoek de bradykinesie 
items. Om de responsiveit te verbeteren zouden de zelfbeoordeelde items uit de ADL sectie 
gehaald moeten worden en in het motorisch onderzoek zou van de tremor items alleen “rust 
tremor armen” behouden moeten worden. 
Het doel in hoofdstuk 3 is om te bepalen welke test voor posturele instabiliteit in een 
klinische setting bij patiënten met de ZvP betrouwbaar, valide en makkelijk uit te voeren is. 
Tweeënveertig patiënten met de ZvP en 15 controle personen namen deel aan de studie. Aan 
de hand van de resultaten van een gestructureerd interview werden de patiënten met de ZvP 
ingedeeld in een ZvP-onstabiele (N=22) en een ZvP-stabiele (N= 20) groep. De retropulsie 
test werd op verschillende manieren uitgevoerd en gescoord. De reacties werden gescoord op 
5 verschillende meetschalen (volgens Nutt, Bloem, Pastor, de Uniﬁed Parkinson’s Disease 
Rating Scale (UPDRS) en de Short Parkinson Evaluation Scale (SPES)). Deze scores werden 
vergeleken met een viertal houdingen die gedurende 5 seconden volgehouden moest worden. 
De overeenkomst tussen de beoordelaars was hoog voor de meeste meetschalen. De gewogen 
kappa’s varieerden van 0.63 voor de UPDRS tot 0.98 voor zowel de Pastor schaal als het 
viertal houdingen. De meeste schalen konden onderscheid maken tussen de ZvP-onstabiele, 
ZvP-stabiele en controle groep. Echter, de totale voorspellende waarde was het hoogst voor 
de Nutt schaal met een sensitiviteit van 0.63 en een speciﬁciteit van 0.88. Concluderend: 
de meest valide test voor posturele instabiliteit bij de ZvP is een onverwachte ruk aan de 
schouder, één keer uitgevoerd waarbij meer dan 2 stappen achteruit als afwijkend wordt 
beschouwd. Deze retropulsie test is makkelijk te gebruiken in een klinische setting.
In hoofdstuk 4 wordt de betrouwbaarheid en validiteit geëvalueerd van de SPES/
SCOPA, een korte schaal die ontwikkeld is om het motorische functioneren van patiënten 
met de ZvP te meten. Vijfentachtig patiënten met de ZvP werden onderzocht met de SPES/
SCOPA, de Uniﬁed Parkinson’s Disease Rating Scale (UPDRS), de Hoehn and Yahr schaal 
en de Schwab and England schaal. Om de betrouwbaarheid tussen twee beoordelaars te 
evalueren werden 34 patiënten twee keer onderzocht, door twee verschillende onderzoekers 
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die blind waren voor elkaars scores en uitvoering van de testen. Bovendien werden zes 
items van de SPES/SCOPA uit het onderdeel motorische stoornissen bij negen patiënten 
onderzocht en op ﬁlm opgenomen om zo de betrouwbaarheid binnen en tussen beoordelaars 
te bepalen. De test-hertest betrouwbaarheid van de somscores van het klinische onderzoek 
was hoog voor alle subschalen van de SPES/SCOPA. Interbeoordelaars betrouwbaarheid 
coëfﬁcienten voor de items varieerden van 0.27 tot 0.83 bij de motorische stoornissen, 
van 0.58 tot 0.82 bij de Activiteiten van het Dagelijks Leven en van 0.65 tot 0.92 in de 
sectie motorische complicaties. Van de motorische items die op video waren opgenomen 
varieerden de betrouwbaarheid coëfﬁciënten tussen beoordelaars van 0.70 tot 0.87 en de 
binnen beoordelaars betrouwbaarheid coëfﬁciënten van 0.81 tot 0.95. De correlaties tussen 
de overeenkomstige subschalen van de SPES/SCOPA en UPDRS waren allemaal hoger dan 
0.85 en beide schalen hadden dezelfde correlaties met andere maten van ziekte ernst. De 
gemiddelde tijd waarin de schalen werden afgenomen verschilde signiﬁcant (p<0.001) en 
was 8.1 minuten (SD 1.9) voor de SPES/SCOPA en 15.6 (3.6) minuten voor de UPDRS. 
De conclusie is dat de SPES/SCOPA een korte, betrouwbare en valide schaal is die zowel 
voor wetenschappelijk onderzoek als in de kliniek gebruikt kan worden om het motorisch 
functioneren van patiënten met de ZvP te meten.
De ontwikkeling van een vragenlijst voor autonome stoornissen bij patiënten 
met de ZvP en de evaluatie van de betrouwbaarheid en de validiteit wordt beschreven in 
hoofdstuk 5. Op basis van de resultaten van een postenquête onder 46 patiënten met de 
ZvP, 21 patiënten met multisysteem atroﬁe (MSA) en 8 specialisten op het gebied van 
bewegingsstoornissen, werden items voor de vragenlijst geselecteerd. De frequentie van 
voorkomen, de hinder die patiënten ondervonden en de klinische relevantie bepaalden of 
items werden geselecteerd. Vervolgens werd de vragenlijst afgenomen bij 140 patiënten met 
de ZvP en 100 controle personen. Om de test-hertest betrouwbaarheid te bepalen vulden 55 
patiënten met de ZvP de vragenlijst een tweede keer in. De SCOPA-AUT bevat 25 vragen 
over de volgende lichaamssystemen: gastrointestinaal (7), urologie (6), cardiovasculair (3), 
thermoregulatoir (4), oog (1) en seksuele (2 voor mannen en 2 voor vrouwen) disfunctie. 
De test-hertest betrouwbaarheid was goed. Met het toenemen van de ziekte ernst namen 
autonome problemen signiﬁcant toe voor alle lichaamssystemen, behalve voor seksuele 
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disfunctie. De conclusie is dat de SCOPA-AUT een betrouwbare en valide vragenlijst is om 
autonome problemen bij de ZvP te evalueren.
In hoofdstuk 6 wordt het onderzoek beschreven naar de validiteit, betrouwbaarheid 
en mogelijke responsiviteit van de de Beck Depression Inventory (BDI) bij patiënten met de 
ZvP. Deze studie werd in twee delen uitgevoerd. In deel 1 ondergingen 92 patiënten met de 
ZvP een gestructureerd klinisch interview voor DSM-depressie en op basis hiervan werden 
patiënten gediagnosticeerd als depressief (ZvP-D) of niet-depressief (ZvP-ND). Daarnaast 
vulden de patiënten de BDI in. Deel 2 bestond uit een enquête die naar 185 patiënten met 
de ZvP en 112 controle personen toegestuurd werd. De test-hertest betrouwbaarheid werd 
bepaald bij 60 patiënten die de BDI een tweede keer invulden. De factor analyse liet een 
cognitief-affectieve en een somatische factor zien. De BDI had een Cronbachs α van 0.88. 
De gemiddelde BDI score verschilde signiﬁcant (p<0.001) tussen de ZvP en controle groep, 
tussen de ZvP-ND en ZvP-D groep en tussen de ZvP-ND en controle groep. In deel 1 liet 
de ROC curve zien dat het oppervlak onder de graﬁek 0.88 was voor de totale BDI. Een 
afkappunt voor de BDI (14/15) werd berekend met de hoogste som van de sensitiviteit 
(0.71) en de speciﬁciteit (0.90). De test-hertest betrouwbaarheid van de totale BDI was 0.89 
(Intraklas Correlatie Coëfﬁciënt). Het kleinste werkelijke verschil was 3.3 voor de BDI. De 
conclusie is dat de BDI een valide, betrouwbaar en mogelijk responsief meetinstrument is 
om de ernst van de depressie bij patiënten met de ZvP te meten, echter met een aangepast 
afkappunt.
De ontwikkeling van een korte en praktische vragenlijst waarbij zowel het slapen 
‘s nachts (NS) als slaperigheid overdag (DS) wordt geëvalueerd (SCOPA-SLEEP) wordt 
beschreven in hoofdstuk 7. Hoewel deze schaal ontwikkeld is voor onderzoek bij de ZvP, 
kan deze ook gebruikt worden bij andere somatische aandoeningen. Honderddrieënveertig 
patiënten met de ZvP en 104 controle personen deden mee aan een enquête waarin 4 
vragenlijsten zaten: de SCOPA-SLEEP NS (5 vragen) en DS (6 vragen), de Pittsburgh Sleep 
Quality Index (PSQI) en de Epworth Sleepiness Scale (ESS). De betrouwbaarheid van de 
SCOPA-SLEEP was hoog: de interne consistentie van de NS en DS schalen was respectievelijk 
0.88 en 0.91 (Cronbachs α) en de test-hertest betrouwbaarheid was respectievelijk 0.94 en 
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0.89 (intraklas correlatie coëfﬁciënt). De scores op de SCOPA-SLEEP verschilden signiﬁcant 
tussen patiënten en controle personen (p<0.001). De construct validiteit werd bepaald door de 
SCOPA-SLEEP te correleren met schalen die vergelijkbare constructen meten. De correlatie 
tussen de NS en de PSQI was 0.83 (p<0.001) en de correlatie tussen de DS en de ESS was 0.81 
(p<0.001). Uit de factor analyse kwam voor beide schalen één factor. Dit betekent dat elke 
schaal één construct meet en daardoor is het gerechtvaardigd om somscores te berekenen. De 
coëfﬁciënt van variatie (CV) van zowel de NS als de DS schaal waren hoger dan die van de 
PSQI en de ESS; dit betekent dat de eerstgenoemde schalen beter in staat zijn om verschillen 
tussen individuen te ontdekken. De conclusie is dat de SCOPA-SLEEP een betrouwbare en 
valide vragenlijst is om het slapen ‘s nachts en slaperigheid overdag van patiënten met de 
ZvP in kaart te brengen.
Het doel van hoofdstuk 8 is om de nauwkeurigheid van het meten van comorbiditeit 
te onderzoeken op basis van een interview bij patiënten met de ZvP. De Cumulative Illness 
Rating Scale-Geriatric (CIRS-G) werd afgenomen door middel van (1) een interview met 31 
patiënten met de ZvP en hun verzorgers en (2) onderzoek van de status van deze patiënten bij 
de huisarts. Op basis van het interview hadden alle patiënten enige comorbiditeit, 84% had 
één of meer matige comorbiditeiten. Het meest frequent aangedaan waren de orgaansystemen 
“onderste deel van de tractus gastrointestinalis” en “tractus urogenitalis”. De gemiddelde 
(± SD) CIRS-G totale score was op basis van het interview 6.9 ± 3.8 en op basis van het 
statusonderzoek 7.6 ± 3.5. Gemiddeld waren op basis van het interview (statusonderzoek) 
4.3 ± 1.9 (5.0  ± 1.9) orgaansystemen aangedaan met gemiddeld  2.1 ± 1.7 (2.3 ± 1.6) 
orgaansystemen met ten minste matige comorbiditeit. De overeenstemming  tussen het 
interview en het statusonderzoek varieerde voor de zes somscores tussen de 0.69 en 0.81 
(intraklas correlatie coëfﬁciënt). De overeenstemming voor de 14 orgaansystemen varieerde 
van 0.13 tot 1.00 (gewogen kappa’s), hiervan hadden 12 orgaansystemen een gewogen 
kappa die meer dan 0.40 was (matige overeenstemming). De CIRS-G somscores hadden een 
matige correlatie met leeftijd en niveau van beperkingen. Concluderend kunnen we zeggen 
dat een interview aan de hand van de CIRS-G een makkelijke en nauwkeurige methode is om 
comorbiditeit te meten bij patiënten met de ZvP.
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Tot besluit
 Om het volledige spectrum en de progressie van de ZvP te beschrijven is het 
“disablement process” een bruikbaar model. Een aantal van deze domeinen zijn in dit 
proefschrift onderzocht. De studies in dit proefschrift laten zien dat de ZvP veel meer omvat 
dan alleen problemen met het bewegen. Ook slaap, depressie en autonome stoornissen zijn 
belangrijke aspecten van de ZvP. Door de beschikbaarheid van betrouwbare, valide en 
praktische meetinstrumenten kunnen deze aspecten van de ZvP makkelijker geëvalueerd 
kunnen worden, zowel bij de behandeling van patiënten als bij het doen van wetenschappelijk 
onderzoek. De aanwezigheid van andere ziektes kan de relatie tussen de ZvP en de mate van 
beperkingen compliceren. Gezien de hoge prevalentie van comorbiditeit zullen de resultaten 
van studies waarin patiënten met comorbiditeit geëxcludeerd zijn, geen goede weergave 
vormen van de algehele populatie van patiënten met de ZvP. Het is daarom belangrijk om 
rekening te houden met het effect van comorbiditeit en een maat voor comorbiditeit mee te 
nemen in studies naar de ZvP.
 Naast de studies die beschreven staan in dit proefschrift, hebben we ook ZvP 
speciﬁeke meetinstrumenten ontwikkeld en onderzocht voor de domeinen cognitie (SCOPA-
COG),1 psychosociale beperkingen (SCOPA-PS),2 een dagboekkaart voor ﬂuctuaties in de 
motoriek (SCOPA-DC)3 en kosten (SCOPA-COST). Bovendien worden op dit moment 
schalen ontwikkeld voor de beoordeling van psychiatrische complicaties en pijn. Een 
aangepaste versie van de Parkinson Psychiatric Rating Scale (PPRS) zal gebruikt gaan 
worden om psychiatrische complicaties in kaart te brengen. De zes oorspronkelijke items 
zijn gedeeltelijk aangepast om het scoren te verbeteren. SCOPA-PAIN is een vragenlijst die 
afgenomen wordt door een onderzoeker. Hiermee wordt de ernst, de duur en het type pijn 
dat de patiënt de afgelopen maand ervaren heeft geëvalueerd. Al deze meetinstrumenten 
samen vormen een complete onderzoeksset waarmee het “disablement process” bij de ZvP 
onderzocht kan worden.
 Het model van het “disablement process” dat in 1999 was gekozen als een 
conceptueel kader voor het onderzoek van de ZvP lijkt veel op het huidige model van de 
Internationale Classiﬁcatie van Functie, Beperking en Gezondheid (ICF)4 van de WHO, 
dat is ontwikkeld in 2002. Het model van het “disablement process” was verkozen boven 
het oude WHO ICIDH model5 omdat het een beter inzicht gaf in de ziekte: een dynamisch 
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model dat ook sociale, psychologische en omgevingsfactoren beschrijft. Het nieuwe 
WHO model ICF is een classiﬁcatie van gezondheid en daaraan gerelateerde domeinen en 
integreert biologische, individuele en sociale perspectieven van gezondheid. Dit model zou 
dus ook een biopsychosociaal model genoemd kunnen worden. De term functie slaat op 
alle lichaamsfuncties, activiteiten en participatie, terwijl beperkingen op een vergelijkbare 
manier stoornissen en beperkingen in activiteiten en participatie omvat. Zowel functie 
als beperking worden gezien als resultaat van interactie tussen gezondheidstoestanden 
(ziekten, aandoeningen, verwondingen) en contextuele factoren (zowel persoonlijke 
als omgevingsfactoren). Nu het model van de ICF en het “disablement process” meer 
overeenkomsten vertonen zouden ze allebei een bruikbaar kader kunnen vormen.
 In de toekomst kan het model van het “disablement process” bij de ZvP uitgebreid 
worden. Op elk niveau waarop de ziekte wordt geëvalueerd kunnen domeinen toegevoegd 
worden als blijkt dat deze onderdeel zijn van de ZvP of een complicatie van de therapie. 
Hoewel bekend is dat de ZvP een enorme impact heeft op de verzorgers van patiënten6;7 
hebben we dit aspect niet speciﬁek in het model opgenomen omdat in het model de patiënt 
centraal staat. Het domein slaap valt nu onder de stoornissen, maar Verbrugge en Jette2;8 
beschouwden het als een beperking: “problemen met de activiteit slapen ‘s nachts”. Echter, 
slaapproblemen kunnen ook beschouwd worden als stoornis en aangezien overmatige 
slaperigheid overdag alleen te duiden is als een stoornis is, is het hele domein slaap verplaatst 
naar de stoornissen.
Toekomstplannen
 SCOPA is een complete en klinimetrisch degelijke onderzoeksbatterij voor de 
ZvP. De meetinstrumenten kunnen zowel los van elkaar als allemaal samen afgenomen 
worden. Afzonderlijk kunnen de meetinstrumenten bijvoorbeeld gebruikt worden om in een 
bevolkingsonderzoek de prevalentie van een parkinson-speciﬁek probleem te bepalen of om 
in een geneesmiddelenstudie het effect van een behandeling te evalueren. Door echter de 
hele onderzoeksbatterij af te nemen kan er beter inzicht in de relaties tussen de domeinen 
verkregen worden en zouden ook subgroepen van patiënten met de ZvP onderscheiden kunnen 
worden. De meetinstrumenten zijn allemaal onderzocht op de betrouwbaarheid en validiteit, 
maar in dit proefschrift is de responsiviteit alleen onderzocht voor de UPDRS-ADL en het 
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motorisch onderzoek. Als de schalen in studies gebruikt gaan worden om veranderingen over 
de tijd te meten, zou het interessant zijn om het minimale verschil dat klinisch belangrijk is 
te berekenen. Dit kan gedaan worden door de verschilscores op de schalen te vergelijken met 
een maat die de verandering meet zoals de patiënt die ervaart. 
 In mei 2003 is het longitudinale SCOPA project van start gegaan. In deze studie 
zullen gedurende 5 jaar 400 patiënten met de ZvP elk jaar onderzocht worden aan de hand 
van de SCOPA schalen. De leeftijd waarop de eerste ziekteverschijnselen ontstaan en de 
ziekteduur zijn belangrijke voorspellers bij de ZvP. Om een cohort van patiënten met de ZvP 
te vormen waarin deze voorspellers gelijk verdeeld zijn, worden patiënten gestratiﬁceerd op 
basis van zowel hun aanvangsleeftijd (< of > 50 jaar) en ziekteduur (< of > 10 jaar). Patiënten 
vullen thuis de vragenlijsten in en de overige meetinstrumenten worden in het ziekenhuis of 
thuis door een onderzoeker afgenomen. Het doel van het SCOPA onderzoek is om binnen 
de ZvP subgroepen te identiﬁceren die verschillen op basis van het type stoornissen die ze 
hebben en de progressie. Tevens wordt gekeken naar de rol van intrinsieke en extrinsieke 
determinanten bij het bepalen van individuele verschillen in het samenspel van de domeinen. 
Kennis over deze onderwerpen is belangrijk om de behandeling van patiënten te kunnen 
verbeteren, maar kan tevens een rol spelen in het vormen van een beter kader voor het meten 
van klinische aspecten in therapeutisch en translatie onderzoek.
SAMENVATTING EN CONCLUSIES
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Nawoord
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